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ABSTRACT 
 
THIOAMIDES IN PROTEASE STUDIES: 
MANY APPLICATIONS FOR A SINGLE-ATOM SUBSTITUTION 
Xing Chen 
E. James Petersson 
 
Proteases are the biological catalysts for a simple yet crucial reaction in living 
organisms, the hydrolysis of amide bonds. Beyond the broad-spectrum degradation of 
proteins, proteases also play key roles in sophisticated physiological processes, and their 
dysfunction and misregulation are implicated in a wide range of human diseases.  Modified 
protease substrates are developed as fluorescent probes to monitor protease activity, and as 
peptide therapeutics to treat protease-regulated diseases.  However, current protease 
substrate modifications are often limited by their relatively large sizes, resulting in 
measurements of disrupted protease activity or in compromised therapeutic activity.  Here, 
we showed that the thioamide, a single-atom substitution in an amide bond, can be 
introduced into protease substrates to develop non-perturbing protease activity probes, or 
to stabilize peptide therapeutics against proteolysis without reducing their physiological 
activity, depending on the modification position. 
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When placed away from the scissile bond of substrates, thioamides can be paired with 
fluorophores to create fluorescent turn-on probes to monitor protease activity in real-time 
under various settings.  We have demonstrated that this strategy can be used to study 
protease kinetics, create highly specific probes for the target protease, and monitor protease 
activity in cell lysates.  When placed near the scissile bond of substrates, thioamides can 
extend the half-life of peptide therapeutics against proteolysis by over 1000-fold while 
maintaining identical bioactivity.  Thioamide-modified anti-diabetic peptides glucagon-
like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) show prolonged in vitro 
half-life and identical potency to activate cell surface receptors.  The best performing GLP-
1 thioamide analog was tested in an oral glucose tolerance test (OGTT) in rats, and dose-
dependent glycemic control superior to that of GLP-1 was observed.  In addition, the 
positional effects of thioamide modification on protease activity was systematically 
investigated to provide guidance of where to place thioamides.  Such studies begin to 
establish rules for how thioamides can be employed in sensor and in peptide stabilization 
applications. 
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1.1  Significance of Proteases in Biological Systems 
General Protease Characteristics  Proteases, also known as peptidases, proteinases, 
or proteolytic enzymes, are enzymes that catalyze the hydrolysis of peptide bonds.  Among 
the most stable chemical bonds commonly found in biological systems, peptide bonds can 
survive in boiling concentrated acid for hours, yet are cleaved by a specific protease within 
seconds1 (Figure 1–1).  To date, 1088 known and putative human proteases are listed in 
the MEROPS protease database, accounting for about 2 % of all proteins2-4.  Based on their 
catalytic mechanism, these human proteases can be grouped into five main classes: aspartic 
acid proteases (~280), cysteine proteases (~250), metalloproteinases (~240), serine 
proteases (~300) and threonine proteases (~40).  In cysteine proteases, serine proteases and 
threonine proteases, a side chain nucleophilic group in the enzyme participates in catalysis, 
forming an acyl-enzyme intermediate which is subsequently hydrolyzed.  In aspartic acid 
proteases and metalloproteinases, an activated water molecule works directly as the 
nucleophile, leading to proteolysis (Figure 1–1, Figure 1–2). 
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Figure 1–1.  Proteases Catalysis.   
 
A)  Proteases catalyze the hydrolysis of peptide bonds.  The hydrolysis of peptide bond is very 
slow without enzymes with a half-life of 610 years.  However, under the catalysis of 1 µM thrombin 
or caspase-3, the proper substrates only have half-lives of 36 min or 1 sec.  B)  Proteases are 
grouped by proteolysis mechanisms.  Cysteine, serine and threonine proteases use covalent 
catalysis, which requires one side chain of the protease to serve as the nucleophile in the active 
site to form an acyl-enzyme intermediate.  Aspartic acid proteases and metalloproteinases use 
general acid-base catalysis, which requires Asp residue or metal ion function as acids and bases 
to activate a water molecule as the nucleophile.  Hydrogen bonding is depicted as dotted line.  
Graphics adapted from Turk2. 
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Figure 1–2.  Catalytic Mechanisms of Different Proteases.   
 
Nucleophilic attack steps in protease catalysis are shown for four classes of proteases.  A)  Serine 
proteases use a Ser residue as the nucleophile.  Conserved catalytic triad, including one Asp, one 
His, and the nucleophile Ser residue, is shown.  B)  Cysteine proteases use a Cys residue as the 
nucleophile, which is deprotonated by a conserved His residue.  C)  Aspartic acid proteases use 
an Asp residue to activate the water molecule.  D)  Metalloproteases use a metal ion to activate 
and coordinate the water molecule as the nucleophile.  Hydrogen bonding is depicted as dashed 
line.  Graphics adapted from Neitzel5. 
 
As one of the best-studied proteases, chymotrypsin is a good example to show the 
catalytic mechanism of proteases (Figure 1–3).  As a serine protease, three residues, Asp102, 
His57 and Ser195 are crucial to the hydrolysis, known as the catalytic triad.  Through 
hydrogen bonding, Asp102 stabilizes and orients the imidazole ring of His57, allowing His57 
to position and polarize the nucleophile Ser195.  After substrate binding (Step 1), the 
hydroxyl group of Ser195 attacks the carbonyl carbon of the substrate, forming a tetrahedral 
intermediate (Step 2).  The intermediate bears a negative charge on the oxygen, which is 
stabilized by hydrogen bonding with N–H groups from the chymotrypsin, termed as 
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oxyanion hole (Figure 1–4).  With an aid of His57 as a general acid, the intermediate then 
collapses, forming the acyl-enzyme (Step 3).  The amine side of the substrate is now free 
to depart as a leaving group from chymotrypsin (Step 4).  A water molecule then deacylated 
the enzyme in a similar fashion as previous steps (Step 5 – 7), and frees the carboxylic acid 
part of the substrate (step 8).   
 
Figure 1–3.  Chymotrypsin Proteolysis Mechanism.   
 
Dashed lines indicate favorable interactions.  Graphics adapted from Berg et al.6 
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Figure 1–4.  The Oxyanion Hole of Chymotrypsin.   
 
The oxyanion hole stabilizes the tetrahedral intermediate in the chymotrypsin hydrolysis.  Hydrogen 
bonding is shown in green dashed lines.  Graphics adapted from Berg et al.6 
 
Proteases recognize their substrates through hydrogen bonding, hydrophobic and 
electrostatic interactions between the substrates and the well-defined active sites (Figure 
1–5).  The recognition elements of the active site are defined by a standard nomenclature.  
Residues from the scissile bond to the N-terminus of substrate are numbered P1, closest to 
the scissile bond, to Pn moving towards the N-terminus.  On the other side of the scissile 
bond, residues are numbered P1' to Pn' from the scissile bond to the C-terminus.  The 
corresponding pockets on proteases that accommodate the specific side chains of substrates 
are designated S1 to Sn and S1' and Sn' respectively.  In addition to the interactions at the 
active site, some proteases may use exosites for further specific recognition of their 
substrates, such as thrombin7, and a variety of metalloproteases including most matrix 
metalloproteinases8.  Exosites participate in substrate binding, but are distal to the active 
site on the protease (Figure 1–5). 
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Figure 1–5.  Protease-Substrate Interactions.   
 
A)  Active site of proteases.  Substrates are cleaved between P1 and P1' residues, depicted by a 
red dotted line.  Starting from the scissile bond, residues are numbered P1-Pn increasingly towards 
the N terminus, and P1'-Pn' increasingly towards the C terminus of the substrates.  The 
corresponding pockets on the protease that accommodate the substrate are denoted as S1-Sn or 
S1'-Sn' accordingly.  Graphics adapted from Turk2.  B)  Substrate-protease binding.  Substrates 
could bind to the exosite of proteases, to further strengthen the specific interaction between 
substrate and protease, on top of the standard interactions in active sites.  Graphics adapted from 
Turk et al.9 
 
Because of the unique function of breaking down proteins, the role of the protease was 
long considered to be nonspecific protein degradation and protein turnover10 since 
Schwann first isolated pepsin in 1836 and Corvisart described trypsin in 1856, both of 
which are essential enzymes to food digestion1, 11.  In the twentieth century, Davie and 
Neurath12 discovered trypsinogen activation in 1955, and Davie and Ratnoff13, as well as 
MacFarland14 explained the blood clotting mechanism in 1964.  Now, proteases are 
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recognized as highly-specific regulators in most biological pathways and their dysfunction 
and misregulation have been implicated in a wide range of diseases1-2.   
Protease Signaling  From the simple to the complex, protease signaling can be 
categorized into four different mechanisms2 (Table 1–1).  Most proteases work alone, 
regulating their substrates by direct peptide bond cleavage, such as the processing of 
cytokine15, ectodomain shedding16, and the maturation of substrates in the secretory 
pathway17.  Protease signaling can also proceed with multiple proteases involved.  In a 
linear pathway, substrates are modified sequentially by several proteases.  In a non-linear 
process, there are also non-protease proteins involved, either as enzymes to modulate the 
substrates or as regulating molecules being modified in the process.  Such examples include 
regulated intramembrane proteolysis18 and the ubiquitin-proteasome pathway of protein 
degradation19.  The most complicated protease signaling is a cascade process, in which 
information is passed by sequential activations of several protease zymogens, that is an 
inactive protease precursor activated by proteolysis.  Well studied proteolytic cascades 
include apoptosis20 and blood coagulation21.  In the blood coagulation pathway, which is 
viewed as the model of proteolytic cascades, sequential activation of a variety of serine 
proteases is involved with thrombin as the final active protease to convert fibrinogen into 
fibrin, leading to the formation of a blood clot.  Although it seems easy to define the 
proteolytic cascade, it is sometimes difficult to validate whether a pathway is a cascade or 
not22.  An example of such a situation is extracellular matrix degradation in cancer, which 
was believed to be a proteolytic pathway, but that is now questioned by substantial amount 
of genetic and biochemical evidence23-24.  Many of the metalloprotease which thought to 
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degrade the matrix might actually be the limited processing proteases whose substrates are 
cytokines and growth factors.  In fact, it is questionable whether proteolytic matrix 
degradation is required for tumor migration at all.  Therefore, it is perhaps more appropriate 
to call them protease networks25. 
Table 1–1.  Selected Examples of Protease Signaling.   
 
Process  
Related Biological 
Functions 
 Proteases Involved Mechanism 
Cytokine processing  Inflammation  Pro-inflammatory 
caspases15 
Single 
Ectodomain shedding  Heart development, 
angiogenesis 
 A disintegrin and 
metalloproteinase 
(ADAM)16 
Single 
Protein maturation in the 
secretory pathway 
 Cell development, 
homeostasis 
 Furin17 Single 
Regulated intramembrane 
proteolysis (RIP) 
 Cell regulation, cell 
signaling 
 Intramembrane cleaving 
proteases (ICLiPs)18 
Non-linear 
Intracellular protein 
degradation 
 Cell life and death  Ubiquitin-proteasome 
system19 
Non-linear 
Extracellular matrix 
degradation 
 Cell differentiation  Matrix metalloproteinases 
(MMP)26-27 
Non-linear 
Blood clotting  Haemostasis  Factor VII, factor X, 
thrombin21 
Cascade 
Apoptosis  Programmed cell death  Caspases20 Cascade 
*  Adapted from Turk2 , and Drag and Salvesen1 
 
Regulation of Protease Activity  Protease activity is spatially and temporally 
regulated not only in terms of transcription and translation, but also at the protein level 
through zymogen activation, cofactor interaction and inhibitor binding.  In addition, 
degradation of proteases can also limit their activity (Figure 1–6). 
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Figure 1–6.  Regulation of Protease Activity.   
 
Protease activity is tightly regulated on different levels, including the transcription level, the 
translation level, and the protein level.  Proteases are usually expressed as inactive zymogens, 
then activated through various mechanisms, such as proteolytic predomain removal, post-
translational modifications (PTMs), cofactor binding, and other environmental changes.  Once 
activated, protease activity is also regulated by endogenous inhibitors and degradation.  Graphics 
adapted from Deu et al.28 
 
On the transcription level, proteases are regulated by differential expression, specific 
to tissue and cell type, as well as developmental stages9.  One such example is caspase-3, 
which is highly expressed in the brain during development29, but greatly downregulated 
during homeostasis and later during senescence30.  On the translation level, protease 
activity and specificity can be regulated by post-translational modifications.  Therefore, 
mRNA levels and protein abundance often fail to identify the active proteases, that other 
approaches are in need to reveal where and when a protease is active. 
Most proteases are synthesized as inactive zymogens, which requires them to be 
activated by proteolysis or conformational change.  This type of activation is strictly 
controlled by distinct mechanisms depending on timing and spatial localization. One 
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example is the family of cysteine cathepsins, which are activated by pH change when they 
reach the lysosome31.  Alternatively, some proteases are activated by forming large 
activation complexes with other proteins, such as the activation of various caspases upon 
formation of the death-inducing signaling complex (DISC)32, or by self-polymerization/ 
compartmentalization as in the proteasome33. 
Cofactors, including proteins and small molecules, regulate protease activity by 
binding to proteases reversibly, often on an allosteric site, or interacting with protease 
inhibitors to prevent their inhibition of proteases.  The most well-known protein cofactor 
example is the regulation of Factor VIIa by tissue factor protein in blood coagulation34.  An 
example of small molecule cofactors is heparin and its derivatives, which are well-
characterized glycosaminoglycans considered as indirect and allosteric inhibitors of Factor 
X35. 
There are also endogenous peptides and proteins regulating proteases by working as 
inhibitors.  However, most endogenous inhibitors can inhibit several proteases, thus 
lacking the specificity to just one target protease.  For example, to all metallo-
endopeptidases found in human, which are more than 180, there are only four main 
inhibitors2.  Those inhibitors usually regulate the target protease activity by controlling the 
physiological concentration, as well as the temporal and spatial colocalization with the 
target protease.  Besides inhibiting protease activity, inhibitors also possess other cellular 
and physiological functions, for example, kininogens, inhibitors of cysteine proteases, are 
also involved in blood pressure regulation36. 
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Proteases and Diseases  As proteases are involved in almost all biological pathways, 
their dysfunction and misregulation is implicated in a variety of diseases.  Some of the best 
known examples are listed in Table 1–2.  In addition, proteases also play a crucial role in 
infection by many pathogens, including viruses, bacteria and parasites.  Thus, quite a few 
small molecule inhibitors targeted to specific proteases have been developed into highly 
successful drugs (Table 1–3).  One of the most significant examples in recent years is an 
inhibitor of dipeptidyl peptidase-4 (DPP-4), sitagliptin (Januvia®; Merck) for the treatment 
of diabetes, with $6 billion annual global sales in 2013.  In fact, it is estimated that proteases 
account for 5 – 10 % of all current pharmaceutical targets under development1.  In addition, 
because of the differential expression levels of proteases in disease, they are also explored 
as biomarkers for disease diagnosis, for example kallikrein 3 has been the major diagnostic 
marker for prostate cancer since 1970s37-38. 
Table 1–2.  Examples of Protease Implicated in Diseases.   
 
Protease Disease 
Thrombin; Plasmin Coagulopathies39; Bleeding disorders40 
Matrix metalloproteinases (MMPs) Cancer25; Inflammation41 
Renin; Angiotensin-converting enzyme (ACE) Hypertension42 
Staphylococcal and streptococcal proteases Necrotic skin infections; Destruction of hemostasis43-44 
Cysteine cathepsins; Caspases; Proteasome Cancer; Neurodegeneration45-47 
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Table 1–3.  Examples of Protease Inhibitor Drugs.   
 
Disease Protease 
Drug Name 
(trade name; company) 
Date on 
Market 
Ref 
Cancer Proteasome 
Bortezomib 
(Velcade; Millennium) 
2003 45 
Coagulation Factor Xa 
Rivaroxaban 
(Xarelto; Bayer) 
2008 48 
Coagulation Thrombin 
Argatroban 
(Acova; GlaxoSmithKline) 
2000 49 
Coagulation Thrombin 
Dabigatran 
(Rendix/Pradaxa; Boehringer Ingelheim) 
2008 50 
Coagulation Thrombin 
Desirudin 
(Revasc/Iprivask; Novartis) 
1998 51 
Diabetes DPP-4 
Sitagliptin 
(Januvia; Merck) 
2006 52 
HIV/AIDS HIV protease 
Tipranavir 
(Aptivus; Pfizer/Boehringer Ingelheim) 
2005 53 
Hypertension ACE 
Captopril 
(Capoten; Brystol-Myers Squibb) 
1981 54 
Hypertension Renin 
Aliskiren 
(Tekturna/Rasilez; Novartis/Speedel) 
2007 55 
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1.2  Detecting Protease Activity In Vivo 
Challenges in Protease Study  Because of their significant roles in almost all 
pathways and a broad spectrum of diseases, proteases have received increasing interest in 
academia and industry.  Although we have seen successful stories of developing potent 
protease inhibitors as drugs (Table 1–3), developing clinically-effective inhibitors remains 
a challenge and numerous failures have also been noted, such as matrix metalloproteinase 
(MMP) inhibitors2.  Several MMP inhibitors were developed to combat cancer because of 
their crucial role in tumor growth, invasion and metastasis56, and achieved promising 
preclinical results.  But they all failed in advanced clinical trials as a result of lack of clinical 
benefit and/or severe side effects2.  The main reasons for this failure are the minimal 
understanding of MMPs’ biology and substrates at that time, as well as lack of target 
specificity from these inhibitors.  In fact, achieving target specificity remains the main 
hurdle in designing protease inhibitor drugs.  This is due to the highly conserved catalytic 
mechanism shared among each protease class, leading to multiple proteases hit by one 
inhibitor, and inadequate understanding of target protease in its native environment, 
resulting in in vivo off-target effects.  Therefore, the need to understand human proteases 
in vivo is of high priority in protease research, and several approaches have evolved in 
recent years to detect protease activity in a biological relevant context28, 57.  Among these 
detection strategies, substrate-based fluorescent turn-on probes garner significant interest 
due to several advantages including high sensitivity, versatility, real-time detection and 
high-throughput ability. 
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Detecting Protease Activity In Vivo  There have been various methods developed 
recently that allow dynamic detection of protease activity in vivo.  Based on the design of 
detecting molecules, these methods can be grouped into three categories: natural substrate 
turnover, substrate-based probes, and activity-based probes (ABPs).  A brief explanation 
of each strategy and some examples of applications will be discussed here briefly, as well 
as the strengths and weaknesses of each strategy. 
Natural Substrate Turnover  The most straightforward way to monitor protease 
activity is to detect the hydrolysis of natural protein/peptide substrates (Figure 1–7).  The 
quantity of cleaved fragments could be used to reflect protease activity, however the 
isolation of cleaved fragments from their native environment is non-trivial.  The most 
common isolation methods include chromatography and gel electrophoresis.  They often 
require a considerable amount of sample which is not always easy to obtain, complex 
procedures for sample preparation and isolation which consume long hours, and a prior 
knowledge of the substrates to be measured.  Alternatively, gel-free enrichment methods, 
taking advantage of the unique α-amino group created from the proteolysis, have also been 
improved, enabling simultaneous identification and quantification of multiple substrates in 
a given sample57-58.  In addition, recent advancement in peptide and protein mass 
spectrometry allows quick and easy detection of substrate turnover, and mass spectrometry 
has been used in the clinic to measure protease activity59-61. 
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Figure 1–7.  Detecting Protease Activity by Natural Substrate Turnover.   
 
The cleavage of substrate by protease (light purple) releases two shorter peptides, which can be 
detected by chromatography, gel electrophoresis, and mass spectrometry.  Graphics adapted from 
Sanman and Bogyo62. 
 
The major advantage of using natural substrate turnover as a proxy of protease activity 
is that the reaction can be monitored in the most undisturbed way, in terms of the substrate, 
the protease monitored, and the environment of the reaction.  Using this strategy, systems-
level monitoring of protease activity has been achieved, revealing the physiological 
functions of proteases and substrate recognition motifs.  Other advantages of this strategy 
include simultaneous monitoring of several proteases and high adaptivity62.  A major 
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disadvantage is that protease activity cannot be monitored in real-time, thus important 
protease kinetics and protease distributions cannot be obtained directly.  Moreover, if the 
natural substrate monitored is subject to multiple proteases, which is usually the case, this 
strategy cannot discriminate among the potential proteases.   
Substrate-Based Probes  Substrate-based probes also rely on the hydrolysis of the 
probe by proteases, but there is no need for isolation or characterization of the cleaved 
products because a specific, measurable signal will be produced when the probe is 
hydrolyzed62-63.  A typical substrate-based probe contains at least two moieties: a 
recognition sequence that would be cleaved by the target protease, and a signal generator 
that would report on the cleavage (Figure 1–8).  The recognition sequence is designed 
carefully to be only identified by the target protease to ensure specificity.  It usually 
originates from nature substrates, or a designed sequence based on knowledge of the active 
site of target protease.  Moreover, peptide library screening is also helpful to obtain a highly 
selective recognition sequence.  Linked to the recognition sequence is the signal reporter, 
which is usually a fluorogenic component so that the signal can be monitored in real-time 
by instruments such as plate readers, fluorescence microscopes, and in vivo imaging such 
as fluorescence flow cytometry and noninvasive animal fluorescence imaging.  In addition, 
a wide variety of chromogenic and luminogenic reporters are also available.  Furthermore, 
magnetic resonance imaging (MRI) substrate-based probes are also developed to 
demonstrate their clinical applicability64. 
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Figure 1–8.  Detecting Protease Activity by Substrate-Based Probes.   
 
A representative substrate-based probe with a fluorophore (lightbulb) and a quencher (red octagon) 
at the two ends of recognition sequence.  The probe does not emit fluorescence before cleavage.  
Upon proteolysis, the fluorescence is released, and can be detected by in vitro fluorescence 
measurements, cell-based in vivo imaging and animal imaging.  Graphics adapted from Sanman 
and Bogyo62. 
 
There are several advantages of substrate-based probes.  Because of the simplicity of 
the design, substrate-based probes could be easily adapted to fit the purpose of the study.  
Unnatural amino acids have been incorporated at the recognition sequence to increase 
specificity to target protease65; many types can be selected as discussed above; substrate-
based probes could also be genetically expressed where fluorescent proteins are used as the 
  
19 
 
 
 
reporters66.  Further discussion about various design of fluorescent substrate-based probes 
is provided in the next section.  Another advantage is signal amplification as one protease 
molecule could process multiple probe molecules producing enhanced signals with low 
background.  Real-time detection, the ability to monitor the proteolytic reaction while it is 
in process at particular cellular locations, is also a big advantage of substrate-based probes, 
enabling interpretation of protease kinetics in cells.  Last but not least, substrate-based 
probes are an essential part of high-through put screening, to profile protease substrate 
specificity and screen for potent protease inhibitors63, 67.  The main disadvantage of 
substrate-based probes is that it relies on the assumption that the probe will only be cleaved 
by the target protease.  Although knowledge about substrate specificity has been developed 
over years, there are still a considerable number of proteases with unknown substrate 
specificity, which may contribute to the cleavage of substrate-based probes.  Another 
possible limitation is that it is difficult to capture the precise subcellular localization of 
target protease because substrate-based probes tend to diffuse freely in the environment. 
Design of Fluorescent Substrate-Based Probes  Based on the fluorescence turn-on 
mechanism, substrate-based probes can be grouped into 4 categories: fluorogenic probes, 
fluorescence resonance energy transfer (FRET) probes, fluorophore-quencher probes, and 
self-quenching probes (Figure 1–9).   
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Figure 1–9.  Fluorescent Substrate-Based Probes.   
 
Fluorescent substrate-based probes can be divided into 4 groups.  A)  Fluorogenic probes.  A 
fluorophore is directly linked to the P1 residue, and the fluorescence is quenched.  Cleavage of the 
fluorogenic probe releases the fluorophore and give out fluorescence signals.  B)  Fluorescence 
resonance energy transfer (FRET) probes.  A FRET probe contains a donor and acceptor 
fluorophore flanking at the two ends.  Excited with the optimal wavelength for the donor, only 
acceptor emission will be observed.  After cleavage, donor and acceptor diffuse away, and only 
donor emission will be observed.  C)  Fluorophore-quencher probes.  A fluorophore and a quencher 
are attached at the two ends of the fluorophore-quencher probe.  When the probe is intact, there is 
no fluorescence emission.  Upon cleavage, the quencher will be separated from the fluorophore, 
and the fluorophore will emit fluorescence.  D)  Self-quenching probes.  Two identical fluorophores 
are installed at different sides of the scissile bond, and will quench each other.  When the probe is 
cleaved, the two fluorophores will be separated and regain their fluorescence.  Graphics adapted 
from Sanman and Bogyo62. 
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In fluorogenic probes, a fluorophore is placed at the P1' position of the substrate, and 
remains quenched.  Upon cleavage, the fluorophore is released and regains its fluorescence, 
giving a turn-on signal.  A commonly used fluorophore is aminomethylcoumarin (AMC) 
(Figure 1–10), and such probes have been developed for a great number of proteases, 
including highly selective probes for different caspases68.  However, fluorogenic probes 
are restricted to the non-primed side of substrates/proteases, and the information of the 
primed side is fully lost.   
 
Figure 1–10.  Chemical Structure of Selective Fluorophores.   
 
A)  Structure of fluorogenic group aminomethylcoumarin (AMC).  AMC is linked to the P1 residue 
by an amide bond.  B)  A FRET pair of fluorescein as the donor and tetramethylrhodamine as the 
acceptor.  They are usually linked to substrates through their carboxylate group.   
 
To study the entire recognition sequence, a FRET probe or a fluorophore-quencher 
probe could be used.  In FRET probes, a FRET fluorophore pair, a donor and an acceptor, 
is placed at the two sides of the scissile bond.  Before cleavage, the donor will transfer 
energy to the acceptor so the acceptor will exhibit higher emission signal.  After the probe 
is cleaved, the donor and the acceptor are separate that energy transfer no longer occurs, 
so an increased emission from the donor will be observed while the emission from the 
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acceptor will decrease.  By monitoring the FRET pair, protease activity can be monitored.  
A common FRET pair includes a fluorescein group as the donor, and a 
tetramethylrhodamine group as the acceptor69 (Figure 1–10, Figure 1–11 and Table 1–4).  
Fluorescent proteins (FPs) with appropriately overlapping spectra are also used in FRET 
probes for monitoring the activity of proteases such as caspases70-72, MMPs73, and Factor 
Xa74.  The unique advantage of such FRET protein probes is that they can be expressed 
endogenously, however they suffer from limitations including low quantum yields and 
overlapping FP excitation and emission spectra making the change in FRET relatively 
small due to direct acceptor excitation72. 
Table 1–4.  Representative FRET Pairs.   
 
Donor (Excitation λmax / Emission λmax)  Acceptor (Excitation λmax / Emission λmax) 
Trp (280 nm / 310 – 350 nm)  IAEDANS (336 nm / 490 nm) 
Coumarin (387 nm / 470 nm)  Fluorescein (490 nm / 525 nm) 
IAEDANS (336 nm / 490 nm)  BODIPY FL (503 nm / 512 nm) 
Fluorescein (490 nm / 525 nm)  Tetramethylrhodamine (557 nm / 576 nm) 
Cy3 (554 nm / 568 nm)  Cy5 (649 nm / 666 nm) 
*  Excitation and emission wavelengths were obtained from Thermo Fisher website75; 
IAEDANS: 5-((((2-iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid 
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Figure 1–11.  Core Structures of Commonly Used Fluorophores.   
 
Typical R groups include CO2-, SO3-, OH, OCH3, CH3, and NO2; Rx position is the typical conjugation 
site.  Adapted from Sapsford et al.76 
 
 
Figure 1–12.  Chemical Structures of Selective Quenchers.   
 
They are usually linked to substrates at the carboxylate group. 
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A more dramatic fluorescence signal difference can be observed in fluorophore-
quencher probes.  They are designed similarly to FRET probes except that instead of a 
FRET pair, a fluorophore-quencher pair is used.  When the fluorophore is excited, energy 
will transfer to the quencher instead of fluorescence emission.  Therefore, spectral overlap 
between fluorophore emission and quencher absorption is required.  Some selective 
quenchers (Figure 1–12) and their quenching ranges are listed in Table 1–5.  By choosing 
the proper fluorophore-quencher pair, a more than 1000-fold fluorescence signal turn-on 
can be observed when the probe is hydrolyzed by the target protease77-78.   
Table 1–5.  Representative Quenchers and Their Quenching Properties.   
 
Quencher  Absorption λmax / nm  Quenched Range / nm 
BHQ-0  495  430 – 520 
BHQ-1  534  480 – 580 
BHQ-2  579  550 – 650 
BHQ-3  680  620 – 730 
QSY-35  475  440 – 500 
QSY-7&9  560  540 – 590 
QSY-21  661  660 – 700 
Eclipse  522  460 – 510 
DABCYL  497  440 – 510 
*  Adapted from BioSynthesis website79 
 
Self-quenching probes are also derived from FRET probes.  Identical fluorophores are 
placed closely so that they will interfere with each other, resulting in quenched 
fluorescence through fluorophore/fluorophore interactions, although the mechanism is not 
always fully understood.  The design of self-quenching probes is quite different from the 
other three types of probes and usually comprise copolymers that display multiple 
fluorophore labelled substrate peptides (Figure 1–13).  The fluorescence is efficiently 
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quenched in the intact copolymer, whereas the cleavage of the probe will free the 
fluorophores leading to an increased emission signal.  Self-quenching probes equipped 
with non-invasive near-infrared fluorescence (NIRF) fluorophores have successfully 
detected cathepsin activity in live cells80 as well as in mice81, and have been used to image 
tumors in mice82.  A variation on the copolymer particle concepts makes use of fluorophore 
labelled substrates linked to inorganic nanoparticles that serve as fluorescence quenchers 
or quantum dots that serve as FRET partners83. 
 
Figure 1–13.  Self-Quenching Probes with Copolymer or Nanoparticle Design.   
 
Self-quenching can take place when multiple fluorescent substrates are attached to A) a copolymer 
or B) a nanoparticle, which is alleviated upon proteolysis.  Graphics adapted from Verdoes and 
Verhelst57. 
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Fluorescent substrate-based probes are powerful tools to study protease activity 
because of their high sensitivity and versatility, but also have limitations from the 
attachment of fluorophores.  Because almost all fluorophores are much bulkier than natural 
amino acids, the incorporation of them may interfere with protease activity, especially if 
the fluorophore is place near the scissile bond or at the scissile bond.  This may be remedied 
by strategic placement of fluorophores far away the cleavage site, but low FRET efficiency 
or quenching efficiency in intact probes may arise as the new problem.  A special case 
worth noting is exopeptidases, which cleave at the terminal or the penultimate peptide bond 
of their substrates.  Due to the extreme limited residues from the scissile bond, it is almost 
impossible to find a proper incorporation place for fluorophores without interrupting 
protease activity.  In fact, a study with dipeptidyl peptidase-4 (DPP-4) clearly showed the 
discrepancy of DPP-4 activity measured from natural substrates and an aminocoumarin 
fluorogenic probe84.  Therefore, less disruptive fluorophores are in need to reflect authentic 
protease activity. 
Activity-based probes  Activity-based probes (ABPs) are composed of three major 
components: the recognition sequence to be cleaved by the target protease, the warhead 
with an electrophile or photocrosslinker to form a covalent bond with target protease, and 
the reporter tag for detection, which is typically an affinity tag or a fluorophore28, 63, 85.  
After covalent bond formation between ABP and target protease, the complex could be 
detected by various technologies, such as gel electrophoresis, mass spectroscopy, 
fluorescence microscopy, and in vivo imaging (Figure 1–14). 
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Figure 1–14.  Detecting Protease Activity by Activity-Based Probes (ABPs).   
 
Activity-based probes (ABPs) bear warheads (maroon triangle) to recognize and link target 
protease covalently.  A)  Fluorescently tagged ABPs can monitor protease activity through in vivo 
imaging and identify active protease species by in-gel fluorescence.  B)  Affinity-tagged (blue star) 
APBs can identify active protease species by immunoblotting or mass spectrometry.  Graphics 
adapted from Sanman and Bogyo62. 
 
Because the covalent bond links the target protease to the probe, it allows direct 
identification and further analysis of the target protease.  This is extremely helpful when it 
comes to evaluation of off-target rates, as well as differentiation among closely related 
proteases28, 63, 85.  However, the presence of the warhead may alter the activity of the target 
protease, and it often limits the exploration of sequences around the scissile bond.  Another 
disadvantage is that once the covalent bond forms, the target protease is inhibited 
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irreversibly, which makes it difficult to monitor variations in the activity of the protease 
over time and may affect cell phenotype63, 86. 
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1.3  Stabilization of Peptide Therapeutics Against Proteolysis 
Proteases as Drug Targets  With a history of more than 60 years and many successful 
examples (Table 1–3), small molecule inhibitors targeted at a protease active site remain 
as the major focus in the field of protease-based drug discovery nowadays.  However, 
failures to develop highly selective active site inhibitors for some proteases have begun to 
shift attentions to other areas, including exosite and allosteric site inhibitors, biological 
inhibitors, and substrate stabilization. 
The difficulty to develop selective active site inhibitors often comes from overlapping 
activity because proteases in the same group have nearly identical active sites.  But exosite 
and allosteric interactions are usually unique to each protease, and therefore will be great 
target sites for selective inhibitors.  The recent discovery of a binding interface distal to the 
active site in the β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) 
provides an example of exosite inhibitors.  BACE1 is responsible for converting APP 
protein into amyloid β (Aβ) peptide, which is implicated in Alzheimer’s disease.  Binding 
of screened peptides to the BACE1 exosite results in a dose-dependent inhibition of this 
proteolysis87.  The potential specificity of allosteric inhibitors has been demonstrated by an 
extremely specific and potent caspase 2 inhibitor88.  Caspases have notoriously overlapping 
substrate specificity, leading to difficulty in developing specific inhibitors89.  Designed 
Ankyrin repeats (DARpins) were screened as inhibitors, and the resulting caspase-2 
specific DARpin interacts with an allosteric site connected with the catalytic center of 
caspase-2.  With these examples, one could envision applying this strategy to develop 
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specific inhibitors for other proteases with many related homologs, such as MMPs and 
deubiquitinating enzymes. 
Another approach is to develop biologicals, including peptides and proteins derived 
from natural inhibitors, to target proteases.  Natural inhibitors often lack selectivity, there 
two strategies are used to gain high specificity: protein engineering and antibody 
conjugation.  Ecallantide (Kalbitor®; Shire), developed from a Kunitz domain, a common 
structure found in many natural inhibitors, through phage display, inhibits plasma 
kallikrein and is used for the treatment of hereditary angioedema90.  Several antibody-based 
inhibitors have been developed through hybridoma technology91 or antibody-display 
screens92-93 for proteases such as MMP-14 and membrane-type serine protease 1.  
Biologicals have the distinct advantage over small molecules in larger interacting surfaces 
with proteases, which may lead to better selectivity.   
An indirect way to target proteases in some special cases is to stabilize the substrates 
against proteolysis.  In the case of a substrate losing its desired activity after proteolysis, 
instead of inhibiting the protease, stabilizing the substrate against proteolysis will achieve 
a similar clinical effect.  One such example is DPP-4 proteolysis of glucagon-like peptide 
1 (GLP-1).  GLP-1 is a peptide hormone regulating insulin level, with great interest in 
diabetes treatment.  However, GLP-1 is deactivated very quickly by DPP-4 hydrolysis with 
a half-life of 2 min in vivo94.  Sitagliptin (Januvia®; Merck) described previously (Table 
1–3) is a small molecule inhibitor of DPP-4 targeting in this pathway.  However, aside 
from GLP-1, DPP-4 also regulate over 25 other peptides with a variety of signaling 
functions.  Therefore, although sitagliptin has seen great success, there have been concerns 
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about the indiscriminate DPP-4 inhibition, which may lead to increased risk of cancer95.  
On the contrary, several forms of stabilized GLP-1, known as “new insulin”, developed 
recently as treatment for diabetes in market do not have such concerns.  In fact, compared 
to protease inhibitors, stabilized substrates have unique advantage of having no off-target 
effects.  Strategies to stabilize protease substrates, and peptide therapeutics in general, are 
discussed here. 
Stabilization of Peptide Therapeutics  Aside from GLP-1, there are more than 7000 
peptides have been discovered in nature, and most of them play a pivotal role as signaling 
molecules, specifically, as hormones, neurotransmitters, ion channel ligands, or anti-
infectives96-99.  They bind to specific receptors, such as G protein-coupled receptors, to 
activate them and then trigger downstream effects.  Because of the potential to use these 
messengers to regulate important biological pathways, peptides have gained a lot attention 
recently.  Currently in the US, there are more than 60 FDA-approved peptide drugs on the 
market, with about 140 peptide therapeutic candidates under clinical trials and more than 
500 peptide medicine is in preclinical development100-101.  The majority of peptide 
therapeutics are hormone analogs, enzyme inhibitors and vaccines.  Peptide therapeutics 
have generated a global market revenue of $14.1 billion in 2011, and this number is 
precited to grow to $25.4 billion in 2018102.  As mentioned earlier, GLP-1 analogs as 
diabetes treatment have seen a huge success in the marketplace, with annual sales of more 
than $2.6 billion in 2013 with liraglutide (Victoza®; Novo Nordisk) alone102. 
Compared to traditional small molecule drugs, peptide therapeutics have unique 
advantages including target affinity and specificity given their large interaction surface 
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with the target.  Compared to large protein drugs, peptides benefit from lower production 
complexity and cost.  However, peptides, especially physiologically native peptides, are 
often not pursued directly as therapeutics because of their potential for immunogenicity 
and short pharmacokinetic half-life due to proteolysis and kidney clearance.  A variety of 
strategies have been developed to tackle the rapid degradation of peptide therapeutic 
candidates by proteolysis, including substitution of relevant residues, reinforcement of the 
structure of the peptides, conjugation to large molecular weight molecules, and 
development of stabilizing formulations (Figure 1–15).  Given our interest in chemical 
modifications, the first three strategies will be discussed in details with examples focused 
on GLP-1 stabilization.   
 
Figure 1–15.  Examples of Chemical Modifications to Stabilize Peptide Therapeutics.   
 
Peptides can be modified in a variety of ways to achieve resistance against proteolysis.  Common 
modifications include terminal modifications, amino acid substitutions, side-chain modifications, 
backbone modifications, and cyclization/stapling. 
 
Amino Acid Substitutions  The stability of peptides against proteolysis can be 
improved by substitutions with unnatural amino acid substitutions or peptide bond mimics, 
(known as peptidomimetics), because these modifications are rarely recognized by 
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proteases (Figure 1–16).  Common unnatural amino acid substitutions include D-amino 
acids, N-methylation and α,α-disubstitution.  For example, in taspoglutide (Roche) (Figure 
1–17), GLP-1 is stabilized with methyl substitutions to block access to the cleavable 
bond103.   
 
Figure 1–16.  Examples of Amino Acid Substitutions and Peptidomimetics.   
 
A)  Structure of native peptide.  B)  Common amino acid substitutions.  Modifications are shown in 
red.  Examples of N-modifications include methylation and hydroxylation.  C)  Common 
peptidomimetics.  Single repeat is shown in blue. 
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Gellman and coworkers have further stabilized GLP-1 by not only substituting at the 
scissile bond, but also making extensive β-amino acid modifications throughout the GLP-
1 sequence (Figure 1–17)104.  Another example is icatibant (Firazyr®; Shire), a bradykinin 
analog for treatment of hereditary angioedema, also incorporating unnatural amino acid 
substitutions (Figure 1–17)105.  A variety of peptidomimetics have also been exploited in 
peptide stabilization, such as peptoids106, urea peptidomimetics107, peptide-carbamates, 
peptide-sulfonamides108, and peptide-peptidomimetic hybrids.  One example of peptoids is 
the peptoid analog of an antimicrobial K6L2W3 model peptide.  The peptoid exhibited 
enhanced resistance against trypsin proteolysis while retaining similar antimicrobial 
activity compared to the native peptide109. 
 
Figure 1–17.  Selective Examples of Unnatural Amino Acid Substitutions in Peptide Therapeutics.   
 
A)  Unnatural amino acid substitutions stabilize GLP-1 against DPP-4 proteolysis.  B)  Icatibant is 
a bradykinin analog with five amino acid substitutions.  Hyp: hydroxyproline.  Adapted from 
Goodwin et al.110 
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Structural Reinforcement  Another way to block proteolysis is to stabilize the 
secondary structure of the peptide by “stapling” strategies, cyclization or structure inducing 
probes111-114.  This reduces proteolysis because most proteases must bind their substrates 
in an extended conformation.   
The stapling strategy, typically applied to induce α-helices, links two residues of the 
peptide by a covalent bond, so that a more stable secondary structure will be maintained.  
Many reactions have been employed for peptide stapling, such as ring-closing olefin 
metathesis115, Cu(I)-catalyzed alkyne-azide cycloaddition (CuAAC)116, alkene-tetrazole 
cycloaddition117 and oxime formation118.  In a recent study with stapled BH3 peptide, 
known to be involved in apoptosis, increased proteolytic stability in serum and cell uptake 
were observed (Figure 1–18)115.  Several groups have also used different stapling strategies 
to stabilize the helical conformation of GLP-1 to restrict access by DPP-4 and increase 
GLP-1R activity119-120.  Similar stapling strategies have been extensively pursued by 
Verdine and others to stabilize and pre-organize other types of helical peptides115, 121.  
Aileron Therapeutics, has advanced stapled peptide candidates for oncology clinical trials. 
 
Figure 1–18.  Stapled BH3 Peptide.   
 
Olefinic residues were introduced by unnatural amino acid substitutions, and formed a covalent 
bond by ruthenium-catalyzed olefin metathesis, inducing enhanced α helical structure. 
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The cyclization strategy is similar to the stapling strategy.  Generally, cyclized 
peptides involve larger cyclic structure than stapled peptides, and are often achieved 
through backbone cyclization.  Most commonly, cyclization was achieved by lactamization 
and sulfide-based linkages such as disulfide bond and thioester bond.  An example of 
cyclized peptides with enhanced resistance against proteolysis is with a peptide fragment 
of glycoprotein D of herpes simplex virus122. 
The structure inducing probe (SIP) technology constrains the target peptide into a 
more ordered conformation by inserting a short peptide sequence into the target peptide, 
forming more intramolecular hydrogen bonds111.  One example is (Lys)6 linked to the C-
terminal of enkephalin exhibited 1000-fold higher stability against leucine aminopeptidase 
compared to the native peptide without (Lys)6
123. 
Large Molecule Conjugation  Various large molecules have been attached to 
peptides to improve their stability, using different mechanisms (Figure 1–19).  
Polyethylene glycol (PEG) conjugation is the most studied large molecule modification to 
peptides, and has a long history in modifying therapeutics to improve their properties115, 
124-125.  PEG is linked site-selectively to peptides via cysteine residues126-128 or unnatural 
amino acids including p-acetylphenylalanine129 and homoazidoalanine130.  For example, 
pegdinetanib, a PEGylated antagonist of vascular endothelial growth factor receptor 2 
(VEGFR-2), has recently completed Phase II clinical trials for colorectal cancer in 2015131.  
However, PEGylation has become less attractive due to the increasing concerns about its 
safety such as immunogenicity. 
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Figure 1–19.  Stabilization Strategies Using Large Molecules.   
 
Selective examples of large molecule conjugations to extend half-life of the target peptide.  PEG 
conjugation is a common peptide modification, and a variety of linking methods are available.  
Albumin binding moieties conjugation, such as lipidation and AlbudAbTM technology132, can 
increase half-life of the target peptide by interacting with abundant albumin in blood streams.  
Albumin can be linked directly to the target peptide to achieve extended half-life.  Neonatal Fc 
receptor (Fc) fragment linked peptides exhibits longer half-lives through FcRn-mediated recycling. 
 
Alternatively, several strategies for conjugating albumin binding moieties or albumin 
protein itself to peptides extend their half-lives.  This strategy slows down proteolysis by 
blocking the cleavable sites of the target peptide, and prevents peptide kidney clearance 
due to the increased molecule weight from albumin.  In addition, through FcRn-mediated 
(FcRn: neonatal Fc receptor) recycling of albumin (Figure 1–20), modified peptides will 
be recycled back to blood streams instead of being degraded.  As similar strategy to prolong 
peptide half-lives via FcRn-mediated recycling is Fc fusion133-134.  There are several 
examples in GLP-1 based therapeutics.  Liraglutide includes a fatty acid modified sidechain, 
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which wraps around the peptide, stabilizes a compact conformation, and binds to 
albumin135-136.  Albiglutide features genetic fusion of two copies of GLP-1 (modified with 
a Gly mutation at the scissile bond) to human albumin to increase circulation half-life by 
both reducing proteolysis and kidney clearance137-138. 
 
Figure 1–20.  Fc-Rn Mediated Recycling.   
 
Fc-fusion or albumin-fusion peptides bind to FcRn on the endothelium, and are internalized into 
endocytic vesicles.  Sorting of FcRn complexes in endosomes separate out receptor-bound 
proteins from non-receptor-bound proteins, which end with degradation.  Receptor-bound proteins 
are recycled back to cell membrane, and the fusion peptides are released back to the blood.  
Reprinted from Mitragotri et al.139 
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1.4  Applications of Thioamide Modification 
Properties of Thioamide Modification  In peptides, amino acids are linked together 
by the standard amide bond, here referred to as an “oxoamide” for clarity.  A thioamide is 
a single atom O-to-S substitution of such amide bond, with different physical and chemical 
properties (Table 1–6)140-142.  The sulfur is slightly larger compared to the oxygen, both in 
terms of van der Waals radius (1.85 Å vs. 1.40 Å)143 and covalent radius (1.02 Å vs. 0.73 
Å)142, and less electronegative (2.58 vs. 3.44)144.  Compared to the C=O bond in oxoamides, 
the C=S bond in thioamides is slightly longer (1.71 Å vs. 1.23 Å)145, weaker in terms of 
bond energy (130 kcal/mol vs. 170 kcal/mol)146, and more polar (5.07 D vs. 3.79 D)147.  
The C−N rotational barrier for the cis-trans isomerization of thioamides is larger than that 
of oxoamides (22 − 25 kcal/mol vs. 20 kcal/mol)148, and thioamides favor the trans 
configuration less compared to oxoamides although both thioamides and oxoamides prefer 
the trans configuration (Figure 1–21)149. 
Table 1–6.  Selected Properties of Thioamides in Comparison with Oxoamides.   
 
Property Oxo Thio 
Van der Waals radius (Å) 1.40 1.85 
C=X bond length (Å) 1.23 1.71 
Electronegativity 3.44 2.58 
Polarity (D) 3.79 5.07 
C=X bond energy (kcal/mol) 170 130 
N−H pKa 17 12 
C=X ∙∙∙ H−N bond dissociation energy (kcal/mol) 6.1 4.8 
π–π* absorption (nm) 200 270 
Oxidation potential (V vs. S.H.E.) 3.29 1.21 
*  S.H.E.: Standard hydrogen electrode 
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Figure 1–21.  Configuration Preferences for Oxoamides and Thioamides.   
 
Regarding hydrogen bonding ability, thioamides are stronger donors but weaker 
acceptors compared to oxoamides.  As hydrogen bond donors, the CSN−H ∙∙∙ O=C bond is 
about 1 kcal/mol stronger than the CON−H ∙∙∙ O=C bond, which is also supported by the 
lower pKa of N−H bond in thioamides compared to oxoamides (18.5 vs. 25.5)150.  This is 
because the N−H bond is more polarized in thioamides, due to the ability of sulfur to 
stabilize the deprotonated anion.  As a hydrogen bond acceptors, the C=S ∙∙∙ H−N bond is 
2 kcal/mol weaker and 0.6 Å longer than the C=O ∙∙∙ H−N bond, as evidenced by both 
experimental151-152 and theoretical studies153.  This is because sulfur is larger and less 
electronegative than oxygen, and the 3sp2 orbital of thioamides forms less effective orbital 
overlap with the 1s orbital of the hydrogen, compared to the 2sp2 orbital of oxoamides. 
Differences in the photophysical and electrochemical properties of thioamides and 
oxoamides underlie several applications in fluorescence spectroscopy, circular dichroism 
(CD) spectroscopy, and photoswitching.  The π–π* absorption of the thioamide occurs at 
270 nm, which is red-shifted relative to the π–π* absorption of oxoamide at 200 nm154.  
This allows simple characterization of a thioamide by absorbance and selective excitation 
in proteins.  There is also a large difference in the oxidation potential between thioamides 
and oxoamides (1.21 eV vs. 3.29 eV)150, which allows for the selective oxidation of 
  
41 
 
 
 
thioamide.  In addition to applications in synthetic peptides, these electrochemical 
properties are responsible for several of the native functions of peptides and proteins that 
contain thioamides. 
Thioamides in Nature  To the best of our knowledge, there are five classes of small 
molecules and one functional protein found in nature containing thioamide bonds.  The 
five classes are represented by cycasthioamide, (4-methoxyphenyl)-N-methyl-2-
oxothioacetamide, apo-methanobactin, thioviridamide, and closthioamide (Figure 1–22).  
Cycasthioamide was isolated from the seeds of Cycas revoluta, with an implication in 
neuronal degeneration upon ingestion155-156.  (4-methoxyphenyl)-N-methyl-2-
oxothioacetamide is from Polycarpa aurata, but is believed to be a degradation product in 
the isolation of the bioactive alkaloid polycarpin157.  Apo-methanobactin was isolated from 
Methylosinus trichosporium, with a role of copper acquisition and trafficking for the 
bacteria158-159.  Further investigation revealed that the thioamides are converted from Cys 
residues in a precursor peptide, but the mechanism remains unknown160.  Thioviridamide 
was isolated from Streptomyces olivoviridis, and induces apoptosis in infected cells161.  
Closthioamide is isolated from Clostridium cellulolyticum, with strong antibacterial 
activity, especially towards S. aureus162.  It contains six thioamide bonds, which are tightly 
associated with its antibiotic ability162-163.  The activity was completely abolished if all 
thioamides were converted to oxoamides, and a significant decrease in activity was 
observed with just one sulfur to oxygen replacement.  The only natural protein found with 
a thioamide is methyl-coenzyme M reductase, which is responsible for methane formation 
in archaea164.  The thioamide is located in the active site region, and is believed to play a 
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role in the electron transfer required for reduction of the methyl-coenzyme M thioether, 
but the exact role of the thioamide is still undetermined. 
 
Figure 1–22.  Chemical Structure of Natural Molecules Containing Thioamide Bonds.   
 
Thioamide in Bioactive Compounds  Thioamides have also seen a great popularity 
in modifying bioactive compounds, and the interest also expands to thioamide derivatives 
including thiazoles, thiazolines, and thiazines165.  Representative examples of thioamide 
modifications include oxytocin166, leucine enkephalin167, and vancomycin168 (Figure 1–
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23).  The first rational thioamide modification was reported by du Vigneaud and coworkers; 
substitution at glycine 9 position of the hormone oxytocin was observed to compromise 
vasodepressor activity166.  Mixed results were observed when thioamides were placed at 
different positions in leucine enkephalin by the Lawesson group167.  Thioamidation at 
tyrosine 1 blocked activity, while thioamidation at glycine 2 increased activity by 3- or 14-
fold depending on the receptors.  In the case of vancomycin explored by the Boger group, 
thioamide substitution eliminated its antimicrobial activity168.   
 
Figure 1–23.  Chemical Structure of Bioactive Compounds Modified with Thioamide Bond.   
 
There are several small molecule drugs containing thioamide moieties as well, such as 6-
n-propyl-2-thiouracil (PTU) as the treatment for hyperthyroidism169.  In summary, mixed 
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results in activities were observed with thioamide incorporation into bioactive compounds 
including small molecules and short peptides, but no studies have been performed in long 
peptides or proteins. 
Thioamides as Photoswitches  Photoisomerization of the thioamide C−N bond can 
be achieved site-specifically in peptides and proteins due to the red-shifted π–π* absorption 
of thioamides.  The photoswitching of thioamides from trans to cis can complete within a 
few hundred picoseconds, while the half-life of thermal relaxation from cis back to trans 
may range from 100 s to 20 min depending on the peptide sequence. Thus, a significant 
amount of cis isomer, up to 40 %, can be accumulated at the photostationary state, 
providing a good system to study the effects of isomerization in biological systems170-173.  
One example is using thioamide photoisomerization to control the enzymatic activity of 
Ribonuclease S (RNase S)172.  Thioamide substitution in the peptide portion of RNase S 
did not alter its activity, but the increased cis to trans ratio of the peptide fragment upon 
irradiation led to decreased activity of the enzyme complex, and activity was restored after 
thermal equilibration. 
Thioamides in Protein Folding  Thioamides have been incorporated into several 
model peptides and proteins to investigate the effects of thioamides on protein folding and 
structural stability.  In monomeric α-helical peptides, a thioamide near the N-terminus or 
C-terminus did not significantly affect folding compared to the all oxoamide peptides, but 
thioamides at positons within the helix showed mixed results174-175.  For β-sheet structures, 
similar structure and stability were observed with thioamides in the sheet region, but 
strategic positioning in the β-hairpin was required to be prevent destabilization176-177.  
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Specifically, when the thioamide was placed at a position that does not participate as a 
hydrogen-bond acceptor, the thiopeptide adopted a stable hairpin structure similar to the 
oxoamide peptide.  More recently, thioamide incorporation effects were examined in more 
complex structures and full-length proteins, including the collagen triple helix, the B1 
domain of protein G (GB1), and calmodulin178-179.  Two studies in collagen model peptides 
showed that thioamide substitution could be dramatically destabilizing at positions where 
it functioned solely as a hydrogen bond acceptor, and moderately stabilizing at positions 
where it functioned solely as a hydrogen bond donor178-179.  In the β-sheet of GB1, 
destabilizing effects were observed from thioamide incorporation, but the impact was 
minimal at strategically chosen position where the longer C=S bond length could be 
accommodated.  Within the C-terminal α-helix and the preceding loop of calmodulin, 
thioamide substitution is well-tolerated in selective positions, and even stabilizing, in 
several positions.  Taken together, these studies show that thioamide effects on protein 
stability can range from destabilization by ~2 kcal/mol to stabilization by ~0.5 kcal/mol.  
These effects depend on subtle differences in local environment; thus, one can vary the 
thioamide substitution depending on whether one wishes to disrupt protein interactions or 
leave them unperturbed.   
Thioamide as Fluorescence Quencher  Our laboratory has developed the 
applications of thioamides as fluorescence quenchers in peptides and proteins.  Thioamides 
are appealing fluorescence quenchers because of their non-perturbing nature in the 
modified proteins and the potential to be easily placed at any given position, as well their 
placement in the backbone, which allows them to directly report on backbone folding.  
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Thioamides have been shown to quench several fluorophores through either FRET or 
photo-induced electron transfer (PeT) mechanisms. 
 
Figure 1–24.  Jablonski Diagram for FRET.   
 
Instead of fluorescence emission, FRET donor transfers energy to excite the acceptor, ending with 
emission from the acceptor or non-radiative relaxation.  Graphics adapted from Olympus Inc180. 
 
As introduced earlier, FRET is a non-radiative way for the energy to transfer from a 
donor fluorophore to an acceptor fluorophore through dipole-dipole interactions.  Upon 
irradiation, the FRET donor is excited. Instead of releasing the energy through fluorescence 
emission, the excited donor transfers the energy to the ground state acceptor, leading to the 
donor relaxing back to the ground state and the acceptor entering an excited state.  The 
acceptor will return to its ground state either by fluorescence emission, as in the 
fluorescein-tetramethylrhodamine FRET pair, or a non-radiative relaxation, as in 
fluorophore/thioamide FRET pairs (Figure 1–24).  The energy transfer efficiency of a 
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FRET pair (EQ) is dependent on the distance between the donor and the acceptor (R), which 
are given by the following equations: 
𝐸Q =  
1
1 + (
𝑅
𝑅0
)6
                                                         (1.1) 
𝑅0
6 =
9000(𝑙𝑛10)𝜅2ΦD𝐽
128𝜋5𝜂4𝑁A
                                                (1.2) 
𝐸Q =  1 −  
𝐹
𝐹0
                                                           (1.3) 
where R0 is the Förster distance at which EQ = 50 %.  R0 can be calculated theoretically 
according to equation 1.2 or determined from experiments.  In equation 1.2, 2 is an 
orientation factor representing the interaction of the transition dipoles of the donor and the 
acceptor, ΦD is the quantum yield of the donor, J is the spectral overlap integral between 
the donor emission and the acceptor absorption,  is the refractive index of the solvent, and 
NA is Avogadro’s number.  Experimentally, R0 can be determined from fitting EQ into the 
Förster equation 1.1, and EQ can be calculated from equation 1.3 based on the 
measurements of donor fluorescence in the presence (F) or absence (F0) of the acceptor. 
For thioamides to quench a fluorophore through FRET, spectral overlap between the 
donor emission spectra and thioamide absorption spectra is required so that thioamide 
FRET partners include tyrosine and p-cyanopheylalanine (Cnf)181-182.  The empirical R0 
was determined to be 16.5 Å for Cnf and 16.2 Å for Tyr (Figure 1–25), enabling these two 
pairs to monitor protein folding and protein-protein interactions.  Representative 
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applications of these FRET pairs include monitoring thermal denaturation of a model 
peptide by a Cnf-Thioamide pair181, as well as quantifying protein-protein interactions by 
a Tyr-Thioamide pair182. 
 
Figure 1–25.  Thioamide Quenching of Fluorescence by FRET.   
 
A)  Thioamide-Cnf FRET pair.  B)  Thioamide-Tyr FRET pair.  Left: Spectra overlap of thioamide 
absorption and fluorophore emission.  The shaded area indicates the spectra overlap that 
contributes to FRET.  Right: Empirical R0 measured by “proline ruler”.  Graphics adapted from 
Goldberg et al.181-182 
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PeT is another non-radiative pathway for a fluorophore to be de-excited by another 
chromophore.  Therefore, the fluorophore and the quencher are required to have matching 
oxidation/reduction potentials, and to be placed in proximity to allow for an electron 
transfer between them.  The Rehm-Weller model183 can be used to determine the Gibbs 
free energy of such electron transfer with the following equation: 
∆𝐺ET = 𝐹[𝐸ox(D) − 𝐸red(A) − 𝐸0,0] + 𝐶                                  (1.4) 
where F is the Faraday constant; Eox(D) is the oxidation potential of the electron donor 
(not necessarily the fluorophore) and Ered(A) is the reduction potential of the electron 
acceptor; E0,0 is the zero vibrational electronic excitation energy of the fluorophore, 
calculated as the average energy of absorption and emission; and C is a term accounting 
for Coulombic interactions, which are typically assumed to be negligible in water.  The 
thioamide has an oxidation potential of 1.21 eV, allowing thioamides to quench a variety 
of fluorophores, including some well-known dyes such as fluorescein, Alexa Fluor 488, 
BODIPY FL and rhodamine 6G141, 184-185 (Figure 1–26).  Because PeT quenching is also 
distance-dependent, occurring at short range, such PeT quenching pairs can be used to 
study protein folding and protein-protein interactions as well.  One preliminary application 
of the fluorescein-thioamide pair is to monitor the refolding of the intrinsically disordered 
protein α-synuclein184, which plays a role in Parkinson’s disease. 
  
50 
 
 
 
 
Figure 1–26.  Thioamide Quenching of Fluorescence by PeT.   
 
A)  A variety of fluorophores are quenched by thioamide through PeT mechanism.  B)  
Fluorescence emission of listed fluorophores (color-coded) in the absence (shaded spectrum) or 
presence of a thioamide (open spectrum below).  Adapted from Goldberg et al.184-185 and Petersson 
et al.141 
 
Incorporation of Thioamides into Peptides and Proteins  In order to utilize the 
unique properties of thioamides, one must be able to incorporate them site-specifically into 
the peptide/protein of interest. 
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The first known thioamide compound synthesis dates back to 1815 when Gay-Lussac 
mixed cyanogen and hydrogen sulfide to obtain dithiooxoamide and 1-
cyanothioformate186-187.  Since then, more reliable and safer methods were developed to 
synthesize thioamides from various precursors including amides, aldehydes, ketones and 
isothiocyanates187-188.  Among those methods, the most direct way to introduce a thioamide 
into peptides is the thionation of oxoamides by phosphorous pentasulfide (P2S5 or P4S10)
189-
190 or Lawesson’s reagent191-192.  However, direct thionation is not selective for a single 
oxoamide in a short peptide, and certainly not in full-length protein187.  Several other 
procedures reported using (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) and its derivatives to activate N-protected amino thioacids 
to introduce a thioamide into peptides193.  Unfortunately, this strategy suffers from low 
yields and purity because of side reactions and racemization.  To introduce a thioamide 
into a specific site in a peptide, a preactivated thioamide precursor is synthesized and then 
coupled to the growing peptide chain in solid phase peptide synthesis.  The Rapoport group 
developed routes using N-Boc (Boc = t-butyloxycarbonyl) protected thioacyl benzotriazole 
precursors, and successfully prepared six thioamide precursors out of 20 natural amino 
acids (except Gly)194.  N-Fmoc (Fmoc = fluorenylmethyloxy-carbonyl) protected thioacyl 
benzotriazole precursors were later explored and evaluated systematically by the Chatterjee 
group195.  In our hands, 13 N-Fmoc protected thioamide precursors have been successfully 
synthesized in a similar fashion, and used to introduce thioamides into peptides (Figure 1–
27).  We have demonstrated the compatibility of thioamide-containing peptides with native 
chemical ligation (NCL) as well as the desulfurization of the Cys at the ligation site196, 
enabling the incorporation of thioamides into full-length proteins178, 182, 185, 196-197. 
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Figure 1–27.  General Synthetic Scheme for Thioamide Incorporation through SPPS.   
 
Graphics adapted from Wang et al.141 
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1.5  Thioamide Modification of Protease Substrates and Inhibitors 
Applications of Thioamides in Protease Studies  Many researchers have attempted 
to harness the unique physical and chemical properties of thioamides to study various 
peptides involved in protease studies, including study of the catalytic mechanisms, attempts 
to make peptide-based protease inhibitors, and in enhancing the proteolytic resistance of 
therapeutic peptides. 
Thioamides to Study Protease Mechanism  To study protease-substrate binding and 
catalytical mechanism, thioamides have been introduced at the scissile bond of protease 
substrates or inhibitors.  Relevant parameters, such as binding affinity for inhibitors and 
Michaelis-Menten kinetic parameters for substrates, were collected and compared to the 
parameters of corresponding oxoamide substrates or inhibitors.  A number of proteases, 
including papain198-200, trypsin199, carboxypeptidase A (CPA)201-204, and Leu 
aminopeptidase (LAP)205-206, have been investigated using thioamide modifications.  The 
most well studied protease is the zinc metalloprotease CPA , whose substrates with a 
thioamide at the scissile bond showed similar KM but at least 10-folds decrease in kcat 
compared to oxoamide substrates (Table 1–7)202-204.  This observation supported a 
mechanism involving the C−N bond rotation as the rate-determining step203.  Moreover, 
several metal ions were tested as CPA cofactors along with the native zinc, to study their 
effects on cleavage of either thioamide-containing substrates or oxoamide counterparts201, 
204.  It was found that thioamide substrates were recognized by Cd(II) CPA, while 
oxoamide substrates could not be cleaved by Cd (II) CPA at all.  A nearly 100-fold increase 
in kcat/KM for Cd(II) CPA relative to Zn(II) CPA was observed for thioamides(Table 1–8).  
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The affinity of sulfur for soft metals supported the mechanism that zinc plays an important 
role to coordinate the C=O group at the scissile bond.  Another example is that thioamide 
at the scissile bond of trypsin substrates almost completely prohibited trypsin proteolysis, 
which was interpreted to be consistent with the important role the oxyanion hole in trypsin 
hydrolysis199. 
Table 1–7.  Kinetic Constants for Thioamide and Oxoamide Proteolysis by Zn(II) CPA.   
 
Substrate 
kcat (sec-1) KM (mM) kcat / KM (M-1∙sec-1) 
oxo thio oxo thio oxo thio 
Bz-Gly-Gly-Phe 020  1.000  2.0 × 104  
Bz-Gly-GlyS-Phe  0.055  4.50  1.2 × 101 
Z-Gly-Ala-Phe 110  0.036  3.0 × 106  
Z-Gly-AlaS-Phe  9.000  0.81  1.1 × 104 
Z-Phe-Phe 450  0.120  3.8 × 106  
Z-PheS-Phe  3.700  0.53  6.9 × 103 
Z-Gly-Phe 055  1.900  2.7 × 104  
Z-GlyS-Phe  5.300  1.10  4.8 × 103 
*  Bz: benzoyl;  Z: N-carbobenzoxy;  GlyS: thioglycine;  AlaS: thioalanine;  PheS: thiophenylalanine; 
Adapted from Bond et al.204 
 
Table 1–8.  kcat/KM Values for Thioamide and Oxoamide Proteolysis by CPA with Different Metals.   
 
Substrate 
kcat / KM (× 106 M-1∙sec-1) 
Zn-CPA Cd-CPA Mn-CPA Co-CPA Ni-CPA 
Z-Gly-Ala-Phe 3.0000 0.970 1.8000 4.500 1.2000 
Z-Gly-AlaS-Phe 0.0110 0.027 0.0017 0.050 0.0035 
Z-Phe-Phe 3.8000 1.300 3.2000 7.200 2.2000 
Z-PheS-Phe 0.0069 0.067 0.0011 0.058 0.0100 
*  Z: N-carbobenzoxy;  AlaS: thioalanine;  PheS: thiophenylalanine;  Adapted from Bond et al.204 
 
Thioamides as Protease Inhibitors  Thioamides were also introduced into protease 
substrates or other peptides to create inhibitors of proteases, including papain198, various 
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proline specific peptidases207-208, LAP206, and HIV-1 protease209.  Almost all thioamide 
inhibitors are found to be competitive inhibitors, but with weak binding affinities.  To our 
knowledge, the first study to use thioamide modification in inhibitors is by Lowe and 
Yuthavong in 1971198.  A thio-glycine was placed at the scissile bond of a papain substrate, 
and behaved as a weak competitive inhibitor with a Ki of 2.3 mM, which was a 100-fold 
increase compared to the KM of the corresponding oxoamide substrate.  A similar result 
was observed for a LAP competitive inhibitor with a thioamide at the scissile bond, whose 
Ki (1.3 mM) is comparable to the KM (5.0 mM) of the oxoamide analog
206.  This strategy 
was further pursued in a HIV-1 peptide substrate with a positional scanning of single 
thioamides from the P3 position to the P2' position (Table 1–9)210.  Interestingly, the most 
potent inhibitor in that study was the one with the thioamide at P2' position rather than the 
scissile bond, with a Ki of 3.4 µM.   
Table 1–9.  Inhibition of Thioamide to HIV-1 Protease.   
 
Peptide  IC50 (μM) 
Boc-ASAF/FVV-OMe  0160 
Boc-AASF/FVV-OMe  0051 
Boc-AAFS/FVV-OMe  0018 
Boc-AAF/FSVV-OMe  >200 
Boc-AAF/FVSV-OMe  000004.5 
*  AS: thioalanine;  FS: thiophenylalanine;  VS: thiovaline;  “/” indicates the cleavage site;  
Adapted from Yao et al.210 
 
Thioamides to Increase Peptide Stability  Thioamide substitutions have also been 
shown to increase peptide resistance to proteolysis, which is particularly useful to peptides 
with therapeutic interests due to the non-perturbing nature of thioamides.  The idea was 
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first tested in 1982, when a CPA substrate with a thioamide at the scissile bond exhibited 
over 1000-fold slower turn-over compared to the corresponding oxoamide substrate203.  
Similar stabilization effects of thioamides at the scissile bond were observed later in 
substrates of LAP206-207, papain200, mammalian membrane dipeptidase209, and 
aminopeptidase P211.  However, in these studies, all thioamide modified peptides are simply 
short peptide substrates of target proteases, without any potential therapeutic interest.   
The first biologically relevant peptide stabilized by thioamides was IMREG-1, an 
immunostimulant with an amino acid sequence TyrGlyGly212.  Two thioamide analogs of 
IMREG-1, TyrSGlyGly and TyrGlySGly (the superscript “S” is used to denote the 
thioamide-containing residues), exhibited significantly increased stability relative to 
IMREG-1 in rat serum, with half-lives of about 46 min and more than 180 min respectively 
as compared to the less than 1 min half-life of native IMREG-1.  However, the 
immunostimulating property of IMREG-1 was impaired with thioamide substitutions such 
that TyrGlySGly showed only weak stimulation of cytotoxic T-lymphocytes when tested 
in vitro.   
The other known example was in polybia-MPI (MPI), a 14 residue α-helical 
antimicrobial peptide exhibiting anticancer activity213.  The C terminal amide of MPI was 
replaced by a thioamide, and enhanced stability against protease degradation in mouse 
serum was observed.  After 3 h incubation in mouse serum, native MPI was almost 
completely gone while 79% of thio-MPI was still intact.  Moreover, thio-MPI suppressed 
tumor growth more effectively than native MPI in vivo. 
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1.6  Summary 
Proteases are the biological catalyst for a simple yet crucial reaction in living 
organisms, the hydrolysis of amide bonds. Beyond the broad-spectrum degradation of 
proteins, proteases also play key roles in sophisticated physiological processes, including 
blood coagulation, apoptosis and cell differentiation. Their dysfunction and misregulation 
are implicated in a wide range of human diseases, such as hypertension, HIV infection, 
neurodegeneration, and cancer.  The greatest challenge in protease research nowadays is 
to understand human proteases in vivo.  Although a variety protease activity probes have 
been developed, they still need improvements due to their shortcomings.  Specifically, 
fluorescent substrate-based probes usually require incorporation of bulky fluorophores, 
which may interfere with the kinetics of proteolysis.  In the current work, we will explore 
the utility of the thioamide, a single atom substitution of the amide bond, as a fluorophore 
quencher to develop non-perturbing fluorescent turn-on probes to monitor protease activity.  
We will also examine the positional effects of a thioamide in substrates of various classes 
of proteases, to guide the incorporation of a thioamide at the optimal position for different 
purposes.  To harness the proteolysis resistance effect of the thioamide at the scissile bond 
of substrates, we will investigate thioamide substitution as a proteolytic stabilization 
strategy for peptide hormones. 
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Chapter 2 .  Thioamide-Based Fluorescent Turn-on Probes for Proteases Activities 
Monitoring in Real-Time 
 
 
 
 
 
 
 
 
 
The content of this chapter was originally published in the Journal of the American 
Chemical Society.  It is adapted here with permission from the publisher: 
Reprinted and adapted with permission from Goldberg, J. M.; Chen, X.; Meinhardt, N.; 
Greenbaum, D. C.; Petersson, E. J., Thioamide-Based Fluorescent Protease Sensors.  J. Am. 
Chem. Soc. 2014, 136, 2086–2093.  Copyright 2014 American Chemical Society.  
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2.1  Introduction 
In order to overcome limitations of current fluorescent protease probes related to 
interference form the placement of two bulky fluorophores near the scissile bond69, 214-215, 
we proposed to use thioamides as minimal perturbing quenchers (Figure 2–1).  Because of 
their much smaller size relative to any other conventional fluorophore or quencher, as well 
as the easy installation into any position of a substrate backbone, thioamides can be placed 
into positions where larger probes would not be well tolerated by a protease.  This 
positional flexibility allows thioamide based probes to provide more thorough, and perhaps 
more accurate information about proteases than any other fluorescence methods. 
 
Figure 2–1.  Scheme for Thioamide-Based Fluorescent Protease probes.   
 
Thioleucine (LS) and 7-methoxycoumarin-4-ylalanine (µ) are placed at the two ends of the substrate 
to create a profluorescent probe for the target protease.  Incubation of the probe with the target 
protease results in cleavage and a fluorescence gain.   
 
An initial trial of this strategy was reported by our group using fluorescein as the 
fluorescent donor184.  Here, this strategy was examined more systematically with another 
fluorescent donor, 7-methoxycoumarin-4-yl-alanine (Mcm; µ) to detect the activity of 
various proteases.  Mcm was chosen for several reasons.  Mcm is significantly smaller than 
fluorescein, only slightly larger than Trp.  It can be incorporated into substrates easily 
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during solid phase peptide synthesis through a commercially available precursor.  As a 
fluorophore, it can be selectively excited in a background of Trp and Tyr residues, and is 
quenched by thioamides to a higher extent compared to fluorescein185.   
Five different proteases were studied by Mcm/thioamide substrates to demonstrate the 
generality of this strategy.  Chymotrypsin and trypsin are both serine proteases, but exhibit 
different substrate specificity.  Chymotrypsin preferably cleaves after aromatic residues, 
namely Tyr, Trp and Phe, while trypsin specifically cleaves after positively-charged 
residues, namely Lys and Arg.  Their substrate specificity comes from the unique structure 
of the S1 pocket of the enzyme.  Papain was chosen as a representative cysteine protease 
because its well-studied catalytical mechanism.  We chose to use thioamide based probes 
to evaluate papain kinetics using rapid-mixing experiments.  Pepsin is an aspartic acid 
protease, with an optimal reaction condition at pH 2.  It was chosen to demonstrate the 
stability and applicability of thioamide based probes in acidic conditions.  Last but not least, 
thermolysin was chosen as a representative metalloproteinase, to test the compatibility of 
thioamide substrates with metal ions. 
In addition to monitoring protease activity in vitro, we also wished to demonstrate the 
utility of thioamide based probes in cell lysates.  Cell lysates systems are much more 
complicated, challenging three aspects of thioamide probes – specificity, stability and 
robustness.  Among a host of different proteases contained in cell lysates, our probe is 
required to be able to specifically recognize the target protease.  In addition, thioamide 
probes should be stable towards nonproteolytic degradation.  Robustness of the probe is 
also important because internal fluorescent materials in cell lysates may contribute to a 
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fluorescent background signal.  To test such properties of our thioamide probes, calpain 
inhibitor efficacy was evaluated in crude cell lysates.  Calpain was chosen because of the 
substantial interest in discovering its reporters and modulators recently216-218.  Calpains are 
a family of calcium-dependent cysteine proteases that have been implicated in a variety of 
physiological processes, including neuronal functions, cell apoptosis and survival, insulin 
secretion, and the regulation of blood vessels219-222.  Recent discoveries also showed that 
calpain activity is linked to malaria223, Alzheimer’s disease224, and breast cancer225.  
Another reason of our interest in calpain is the unusual helical conformation of its substrate 
peptide in the active site, unlike the typical extended conformation of many substrates226.  
Therefore, we designed our probe based on the amino acid sequence of natural substrates 
to confer specificity for calpains. 
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2.2  Results and Discussion 
We began our investigation by preparing thioamide/fluorophore doubly labeled 
peptides as fluorescent turn-on probes.  Thioamides, denoted by the one or three letter code 
of the corresponding natural amino acid with a superscript S, e.g., LS, is placed at the N-
terminus, and the fluorophore, 7-methoxycoumarin (Mcm; µ), is placed at the C-terminus.  
Two peptide sequences, ASAFAμ and LSLKAAμ, were chosen to be recognized as 
substrates of different classes of proteases, including chymotrypsin, papain, pepsin, 
thermolysin, and trypsin (Figure 2–2, Figure 2–9).  As a control, the corresponding all 
oxoamide version of each peptide, AAFAμ and LLKAAμ, were also synthesized.  In a 
typical experiment, the thioamide-containing peptide was incubated with a protease, and 
the time-course of fluorescence intensity was monitored.  The fluorescence of thiopeptide 
in the absence of the protease, as well as the corresponding oxopeptide in the presence and 
the absence of the protease was also monitored to serve as controls.  In the absence of 
proteases, the thiopeptide ASAFAμ was quenched ~ 65 % relative to the control peptide 
AAFAμ, and the thiopeptide LSLKAAμ was quenched ~ 40 % relative to the control 
peptide LLKAAμ.  The fluorescence of both thiopeptide and oxopeptide remained constant 
in the absence of proteases, with slight decreases probably due to photo-bleaching.  In the 
presence of an appropriate protease, an immediate fluorescence increase was observed 
upon the addition of protease to the thiopeptide, while no fluorescence change with the 
oxopeptide. 
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Figure 2–2.  Steady State Assays of Thioamide as Protease Activity Probes.   
 
Representative results of chymotrypsin, pepsin, papain, and thermolysin experiments were shown.  
Red trace: thiopeptide in the presence of protease; Orange race: thiopeptide in the absence of 
protease; Green trace: corresponding oxopeptide in the presence of protease; Blue trace: 
corresponding oxopeptide in the absence of protease. 
 
Further investigations were conducted to ensure the fluorescence increases observed 
were indeed the result of proteolysis of thiopeptides.  These experiments were repeated 
with heat-deactivated proteases to ensure the fluorescence changes were due to protease 
activity (Figure 2–10).  The fluorescence of the thiopeptide in the presence of an inactive 
protease remained constant, identical to that of the thiopeptide in the absence of protease.  
To further ensure that the fluorescence changes were the result of proteolysis of 
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thiopeptides, and to validate that the oxoamide control peptides also underwent proteolysis 
though no fluorescence changes were observed, the papain reactions were analyzed by 
high-performance liquid chromatography (HPLC) at various time points (Figure 2–11).  
The chromatograms of the peptides remained the same over time in the absence of papain.  
In the presence of papain, the signal of the starting material decreased and the signal of the 
expected cleavage products increased, which were identified by Matrix-assisted laser 
desorption ionization with time-of-flight detector mass spectrometry (MALDI-TOF MS).  
The results also demonstrated that thiopeptides exhibited minimal perturbation to protease 
activities since the cleavage rates of thiopeptide and oxoamide peptide were roughly the 
same.  Additional experiments with thiopeptides that were not subjected to papain 
proteolysis provided further evidence that the presence of a thioamide-based sensor does 
not trigger proteolysis (Figure 2–12). 
To demonstrate the feasibility of using thioamide probes to study protease kinetics, 
representative stopped-flow experiments with papain and LSLKAAμ of variable initial 
concentrations were performed.  A three-step reaction scheme could be used to describe 
papain catalysis (Figure 2–3, Top).  From this scheme, an expression for papain cleavage 
rate can be developed and globally fit to the data from stopped-flow experiments (Figure 
2–14).  Following kinetic parameters were obtained from the global fitting: KS = k1/k-1 = 
921 μM, k2 = 0.92 s-1, k3 = 0.057 s-1, from which kcat = 0.054 s-1 and KM,app = 53.9 μM were 
determined.  The concentration dependence of papain activity was observed in the stopped-
flow primary data plot and the initial rates extrapolated from the data (Figure 2–3, Bottom).  
The initial rates were fitted to the standard Michaelis-Menten equation, and nearly identical 
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kcat and KM values were obtained: kcat = 0.057 ± 0.001 s
-1 and KM,app = 50.2 ± 1.1 μM 
(Figure 2–14).  The catalytic efficiency, kcat/KM, calculated as 1.00 × 103 M-1•s-1, was 
similar to that previously reported of papain measured by substrate lysylnitroanilide (2.57 
× 103 M-1•s-1)227.  A wide variety of rates were reported for the same enzyme studied by 
different fluorogenic substrates228-230.  The small size of thioamide renders our probes 
nearly identical to the actual substrate, which would ensure that the measurements obtained 
from our probes are relevant to the actual protease substrates. 
 
Figure 2–3.  Papain Kinetics Determined by Stopped-Flow Experiments.   
 
Top:  Reaction scheme for papain proteolysis with rate constants as defined.  E: enzyme; S: 
substrate; ES and ES': enzyme-substrate complexes; P and Q: products.  Left:  Fluorescence 
change monitored by stopped-flow for papain proteolysis of thioamide-based probes.  Selective 
runs are shown for clarity.  Inset:  A representative burst phase and the fit.  Right:  Michaelis-Menten 
fit of reaction rates determined from stopped-flow.  Data are color-coded based on initial substrate 
concentration, and details could be find in 2.5 Materials and Methods. 
 
It would be particularly valuable if one thioamide probe with two protease cleavage 
sites could distinguish between these two proteases.  It is difficult for conventional 
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fluorophore quenchers because of the specific incorporation locations and disruptive large 
sizes.  On the contrary, thioamide could be incorporated at different locations without 
perturbing the native peptide structure.  To test such ability of thioamide probes, the dual-
sites peptide AKGLSAAFAμ was prepared that the cleavage of chymotrypsin before the 
Phe residue would lead to a fluorescence increase, while the cleavage of trypsin before the 
Lys residue would not, since the fluorescence of μ would remain quenched by thioamide 
in the cleaved fragment GLSAAFAμ.  Similar steady state assays were conducted using 
dual-sites probe AKGLSAAFAμ with chymotrypsin or trypsin.  The results showed an 
immediate turn-on of fluorescence when the thiopeptide was incubated with chymotrypsin 
(Figure 2–4, Left).  Such fluorescence increase was not observed in the absence of 
chymotrypsin, or with the control oxoamide peptide AKGLAAFAμ.  No fluorescence 
change was observed when the thiopeptide was incubated with sequencing grade trypsin 
over 2 h (Figure 2–4, Right).  However, the cleavage of trypsin had indeed occurred at the 
expected site of AKGLSAAFAμ, indicated by HPLC and MALDI-TOF MS analysis 
(Figure 2–16).  HPLC analysis also showed that thiopeptide and the control oxopeptide 
were cleaved at approximately the same rates.  It is worth mentioning that when lower 
grade trypsin was used, a slow turn-on of fluorescence was observed from trace 
chymotrypsin mixed with the trypsin reported by the manufacturer (Figure 2–15).  We 
expect the results observed with AKGLSAAFAμ to be general, that thioamide could be 
incorporated in an otherwise native sequence to monitor a specific cleavage event in real 
time. 
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Figure 2–4.  Selective Recognition of Chymotrypsin of a Dual-Sites Thiopeptide.   
 
Steady state assay of AKGLSAAFAμ with chymotrypsin or trypsin.  /: Cleavage site of the protease 
in the peptide.  Red trace: thiopeptide in the presence of protease; Orange race: thiopeptide in the 
absence of protease; Green trace: corresponding oxopeptide in the presence of protease; Blue 
trace: corresponding oxopeptide in the absence of protease. 
 
Finally, we wished to demonstrate the ability of thioamide-containing peptides as 
protease probes to monitor protease activity in cell lysates.  The stability of thioamides 
towards nonproteolytic degradation was examined before the cell lysate assay.  Although 
backbone thioamides exist in natural peptides and have shown a certain degree of metabolic 
resistance, we were only able to find one published evaluation of their stability applicable 
to our studies212-213, 231.  Specifically, “thiopeptides”, does not include the well-studied 
thiazoline232, but only refer to acyclic thioamides incorporated in peptides.  To assess 
thioamide stability, a biotin-labeled thiopeptide with D-amino acids, Biotin~FSaa (where a 
represents D-alanine), was prepared.  This peptide should report on only nonproteolytic 
degradation from metabolism, since it is not recognized by any protease.  Biotin~FSaa was 
incubated in PBS or mouse serum at 37 °C for up to 24 h, then recovered using neutravidin 
beads, and analyzed by HPLC.  A biotin-labeled coumarin dipeptide was also incubated in 
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the presence of reaction mixture, to serve as a control.  The results showed that Biotin~FSaa 
was completely intact after 1 h and was recovered 94 ± 2 % after 24 h in PBS.  In mouse 
serum, it was found to be 85 ± 2 % recoverable after 1 h and 80 ± 2 % recoverable after 4 
h.  While we continue further experiments to understand the 20% loss, we are confident 
about the stability of thiopeptide probes in cell lysates assays since most of our assays are 
completed within 2 h. 
We began by evaluating our thiopeptide probe, LSPLFAERμ, with purified calpain 1 
in buffer.  A fluorescence increase was observed only when LSPLFAERμ was incubated 
with calpain in the presence of Ca2+.  No fluorescence gain was observed with the control 
oxopeptide, LPLFAERμ, or with the thiopeptide in the presence of EDTA, a Ca2+ chelator, 
resulting in inhibition of calpain activity (Figure 2–19).  The probe was carried on to be 
tested in cell lysates of mouse embryonic fibroblast (MEF) cells, which contain 
endogenously-expressed calpain 1 and calpain 2.  In the presence of externally added Ca2+, 
a fluorescence increase was observed when the thiopeptide LSPLFAERμ was incubated in 
cell lysates (Figure 2–5, Right, trace E, pink).  In the presence of added EDTA, no 
fluorescence increase was observed from LSPLFAERμ in cell lysates (Figure 2–5, Right, 
trace F, blue).  However, when the fluorophore, 7-methoxycoumarin (μ), was incubated in 
cell lysates alone, a small fluorescence increase was also observed, probably due to non-
specific fluorophore aggregation in the complicated cell lysates environment (Figure 2–5, 
Left and Right, trace μ, black).  In the presence of a saturating concentration of a calpain-
specific inhibitor226, Calpastatin peptide, the fluorescence change over time was nearly 
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identical to that of the fluorophore alone, indicating the full inhibition of calpain activity 
(Figure 2–5, Right, trace D, purple).   
 
Figure 2–5.  Evaluation of Calpain Inhibitor Efficacy in Cell Lysates.   
 
Top: Experimental setup.  Left: Relative fluorescence change of ASAFAμ in MEF cell lysates.  Right: 
Relative fluorescence change of LSPLFAERμ in MEF cell lysates. 
 
To demonstrate the specificity of LSPLFAERμ to calpain, a non-specific thioamide 
probe, ASAFAμ, was also tested in the same experiments.  A fluorescence increase was 
also observed from ASAFAμ when it was incubated in cell lysates in the presence of Ca2+ 
(Figure 2–5, Left, trace B, red), but only a small fraction of the fluorescence increase could 
be inhibited by the calpain inhibitor (Figure 2–5, Left, trace A, yellow).  Furthermore, a 
considerable amount of fluorescence increase was still observed even upon addition of 
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EDTA, showing non-specific cleavage of ASAFAμ from proteases other than calpain 
(Figure 2–5, Left, trace C, green).  Collectively, these data showed the eligibility of 
thiopeptides as fluorescent probes of protease activity in cell lysates, and that thioamide 
probes could be designed highly specific to monitor the activity of only one protease. 
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2.3  Conclusion 
We have successfully demonstrated the ability of thioamide-based fluorescent probes 
for monitoring protease activities in real time under various settings.  Steady state assays 
were conducted as proof-of concept examples with a variety of proteases, including trypsin, 
chymotrypsin, pepsin, papain and thermolysin.  Three model applications were then carried 
out to show the value of this strategy.  First, papain kinetics was characterized by 
thioamide-based probes using rapid-mixing experiments, giving kinetic parameters similar 
to previous reported values.  Second, selective monitoring of chymotrypsin over trypsin 
was demonstrated with a thioamide-based probe bearing cleavage sites of both proteases.  
Last, but not least, calpain inhibitor efficacy was analyzed in cell lysates with a calpain-
specific thioamide-based probe.  Meanwhile, we have also demonstrated that thioamide 
incorporation showed no disruption in protease activities compared to their oxoamide 
control peptides, unlike some other fluorophores233-235.  In conclusion, we have explored a 
new strategy to design fluorescent probes for protease activity, with great specificity and 
minimal disruption in complicated environment like cell lysates. 
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2.4  Future Directions 
Given the success of thioamide probes in cell lysates, we expect to be able to expand 
this strategy to applications in cell culture, that is to monitor protease activity in real time 
on cell surface or in cells (Figure 2–6). 
 
Figure 2–6.  Thioamide Probes to Monitor Protease Activity on Cell Surfaces or in Cells.   
 
For on-cell activity probes, collagenase would be an interesting protease to monitor 
on the surface of normal cells and breast cancer cells, since collagenase is over-expressed 
in breast cancer cells and responsible for cancer cell invasion236-237.  For live cell imaging, 
a bright and red-shifted fluorophore is needed to be paired with thioamides.  Our 
preliminary data showed that the thiopeptide ψAAGPAAS-NH2 (ψ represents Fam-Cys) 
was able to monitor purified collagenase activity in buffer (Figure 2–7).  After further 
optimization of the specificity of our thioamide probes to collagenase, our probes would 
be able to observe the differential activities of collagenases on the surface of live breast 
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cancer cells and normal cells.  Based on this, we envision that this platform can be used to 
analyze sequence specificity or in screening for collagenase-targeted cancer drug discovery. 
 
Figure 2–7.  Thioamide Probes to Monitor Purified Collagenase Activity.   
 
A)  Chemical structure of ψ.  B)  Thiopeptide ψAAGPAAS-NH2 in the presence of collagenase. 
 
For in-cell activity probes, thioamide probes will be attached with a poly-Arg or other 
cell-penetrating peptide sequence to enable its entrance into cells.  If non-proteolytic 
degradation is minimal within the time frame of interest, our cell-penetrating thiopeptide 
probes can be used in the next stage to monitor the proteases activity in their native 
environment. 
Because of the small size and non-disruptive features of thioamides, we believe it 
would provide a significant improvement over other fluorescent protease probes.  Although 
there are situations in which protease activity is not affected by the incorporation of 
fluorophores in the substrate, many examples are found where fluorophore incorporation 
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disturbs the observed kinetics, such as papain233-235.  One way to obviate such problems is 
to place the fluorophores far away from the cleavage site, which results in a loss of 
information about the specificity of the protease, or is not viable in the case of 
aminopeptidases.  By exploiting the feature of thioamides that they can be placed at 
virtually any position, we would be able to create new protease probes without disturbing 
protease kinetics while obtaining information about substrate specificity. 
Finally, while short thiopeptide probes can be very useful for a broad range of assays, 
we also envision applying this method to analyzing the proteolytic stability of full-sized 
proteins, particularly in addressing protein autoproteolysis or proteolysis in multiprotein 
complexes.  A first target of interest is α-synuclein (αS), a neuronal protein whose 
aggregation is linked to Parkinson’s disease. Previous studies showed that aggregation is 
much accelerated in proteolytic fragments of αS, and an αS autoproteolysis phenomenon 
has been reported238-242.  It would be interesting to examine the mechanisms of these 
processes using our thioamide strategy, and to understand their physiological significance 
in live neurons. 
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2.5  Materials and Methods 
General Information  Fmoc-D-Ala-OH was purchased from GenScript (Piscataway, 
NJ, USA).  Other Fmoc protected amino acids and 2-chlorotrytyl resin were purchased 
from Novabiochem (currently EMD Millipore, Billerica, USA).  Boc-L-thionoleucine-1-
(6-nitro)benzotriazolide, Boc-L-thionoalanine-1-(6-nitro)benzotriazolide, and Fmoc-β-(7-
methoxycoumarin-4-yl)-Ala-OH were purchased from Bachem (Torrance, CA, USA).  
Piperidine and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU) were purchased from American Bioanalytical (Natick, MA, USA).  Sigmacote®, 
N,N-diisopropylethylamine (DIPEA), mouse serum, trypsin (lyophilized powder; from 
porcine pancreas; Type II-S; 1,000 – 2,000 units/mg dry solid), chymotrypsin (lyophilized 
powder; from bovine pancreas; Type II; ≥ 40 units/mg protein), thermolysin (lyophilized 
powder; from Bacillus thermoproteolyticus rokko; 50 – 100 units/mg protein), papain 
(crude powder; from papaya latex; 1.5 – 10 units/mg solid), and pepsin (lyophilized powder; 
from porcine gastric mucosa; 3,200 – 4,500  units/mg protein)  were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).  Native calpain-1 from human erythrocytes was 
purchased from Calbiochem (currently EMD Millipore).  Calpastatin peptide (sequence: 
Biotin-Asp-Pro-Met-Ser-Thr-Tyr-Ile-Glu-Glu-Leu-Gly-Lys-Arg-Glu-Val-Thr-Ile-Pro-
Pro-Lys-Tyr-Arg-Glu-Leu-Leu-Ala-NH2) was purchased from Auspep (Tullamarine, 
Victoria, Australia).  All other reagents were purchased from Fisher Scientific (Pittsburgh, 
PA, USA) unless otherwise specified.  Milli-Q filtered (18 MΩ) water was used for all 
solutions (EMD Millipore).  UV-Vis absorption spectra were acquired with a Hewlett-
Packard 8452A diode array spectrophotometer (currently Agilent Technologies; Santa 
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Clara, CA, USA).  Matrix-assisted laser desorption ionization with time-of-flight detector 
(MALDI-TOF) mass spectra were collected with a Bruker Ultraflex III MALDI-TOF-TOF 
mass spectrometer (Billerica, MA, USA).  Peptides were purified with a Varian ProStar 
High-Performance Liquid Chromatography (HPLC) instrument outfitted with a diode array 
detector (currently Agilent Technologies).  Reaction mixture were analyzed on an Agilent 
1100 series HPLC system (Agilent Technologies). 
Peptide Synthesis and Purification  Each peptide was synthesized on a 12.5 μmol 
scale on 2-chlorotrityl resin.  Glass peptide synthesis reaction vessels (RVs) were coated 
with Sigmacote® prior to use. For a typical synthesis, 2-chlorotrityl resin was added to a 
dry RV, and swelled in 5 mL dimethylformamide (DMF) for two successive 15 min with 
magnetic stirring.  Between each step, the resin beads were washed thoroughly with DMF.  
For the first amino acid coupling, 5 equiv. of amino acid in 1.5 mL DMF and 10 equiv. of 
DIPEA were added to the RV, and the reaction was allowed for 30 min under stirring.  
After washing, the resin was treated with 2 mL of 20 % piperidine solution in DMF for 20 
min under stirring for deprotection.  Subsequent amino acid couplings and deprotections 
were proceeded following the same procedures, with the exception that 5 equiv. of HBTU 
was added in each coupling reaction to activate amino acids.  Thioamide was introduced 
through pre-activated precursors, so the coupling reaction was proceeded without HBTU.  
Upon completion of the synthesis, the resin was dried with CH2Cl2 under vacuum.  Peptides 
were cleaved off resin by treatment of 2.5 mL of a fresh cleavage cocktail of trifluoroacetic 
acid (TFA), water, and triisopropylsilane (TIPS) (10:9:1 v/v) for successive 60 min and 30 
min on a rotisserie.  For AKGLSAAFAµ, a cleavage cocktail of 5% TFA in CH2Cl2 with 
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2.5% TIPS was used.  After each treatment, the resulting solution was expelled from the 
RV with nitrogen, reduced to a volume of less than 1 mL by rotary evaporation, and diluted 
with 6 mL of CH3CN/H2O (2:1 v/v).  The peptides were then purified on a Vydac 218TP 
C18 semi-prep column (Grace/Vydac; Deerfield, IL, USA) by HPLC using the following 
gradients (Table 2–1,Table 2–2).  MALDI-TOF MS was used to confirm peptide identifies 
(Table 2–3).  Purified peptide were dried in a vacuum centrifuge (Savant/Thermo 
Scientific; Rockford, IL, USA). 
Table 2–1.  Peptide Purification Methods and Retention Time.   
 
Peptide Gradient Retention Time 
AAFAμ 1 23 min 
ASAFAμ 1 23 min 
LLKAAμ 2 22 min 
LSLKAAμ 2 22 min 
AKGLAAFAμ 3 15 min 
AKGLSAAFAμ 3 15 min 
LPLFAERμ 4 17 min 
LSPLFAERμ 4 17 min 
FSaa (1) 1 18 min 
Biotin~FSaa (3) 1 27 min 
μ (5) 5 13 min 
Biotin~μ (6) 6 20 min 
*  μ: 7-methoxycoumarinylalanine;  AS: thioalanine;  LS: thioleucine;  a: D-Alanine 
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Table 2–2.  HPLC Gradients for Peptide Purification and Analysis.   
 
No. Time (min) %B  No. Time (min) %B 
1 00:00 002  2 00:00 002 
06:00 002  06:00 002 
25:00 040  20:00 030 
30:00 100  30:00 040 
40:00 100  35:00 100 
45:00 002  40:00 100 
   45:00 002 
3 00:00 002  4 00:00 002 
06:00 002  06:00 002 
10:00 033  12:00 030 
25:00 037  32:00 050 
30:00 100  47:00 100 
35:00 100  52:00 100 
40:00 2  57:00 002 
5 00:00 002  6 00:00 002 
06:00 002  06:00 002 
10:00 020  20:00 050 
25:00 035  25:00 100 
30:00 100  30:00 100 
35:00 100  35:00 002 
40:00 002    
7 00:00 002     
06:00 002    
10:00 020    
21:00 031    
25:00 100    
30:00 100    
35:00 002    
*  Solvent A: 0.1 % TFA in water;  Solvent B: 0.1 % TFA in acetonitrile 
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Table 2–3.  Calculated and Observed Purified Peptide Masses.   
 
Peptide 
[M+H]+ [M+Na]+ 
Calculated Observed Calculated Observed 
AAFAμ 0624.27 0624.36 0646.25 0646.33 
ASAFAμ 0640.24 0640.30 0662.23 0662.27 
LLKAAμ 0760.42 0760.55 0782.41 0782.52 
LSLKAAμ 0776.40 0776.39 0798.38 0798.36 
AKGLAAFAμ 0993.51 0993.81 1015.49 1015.80 
AKGLSAAFAμ 1009.48 1009.77 1031.46 1031.75 
LPLFAERμ 1090.56 1090.48 1112.54 1112.46 
LSPLFAERμ 1106.53 1106.60 1128.52 1128.59 
FSaa (1) 0324.14 0324.08 0346.12 0346.04 
Biotin~FSaa (3) 0713.23 0713.42 0735.21 0735.19 
μ (5) 0264.09 0264.20 - - 
Biotin~μ (6) 0653.18 0653.33 0675.16 0675.32 
*  μ: 7-methoxycoumarinylalanine;  AS: thioalanine;  LS: thioleucine  a: D-Alanine 
 
Biotinylated Substrate Synthesis  Biotinylated peptides were synthesized 
according to Figure 2–8.  0.5 µmol of FSaa (compound 1) was mixed with 0.5 µmol of EZ-
Link Sulfo-NHS-Biotin (compound 2) in 250 µL of sodium phosphate buffer (20 mM, pH 
7.20) to synthesize Biotin~FSaa (compound 3).  The reaction was allowed to proceed at 
room temperature for 2 h, then Biotin~FSaa (compound 3) was purified by HPLC (Table 
2–1,Table 2–2) and confirmed by MALDI-TOF MS (Table 2–3).  Biotin~µ (compound 6) 
was prepared analogously.  82.2 mg of Fmoc-β-(7-methoxycoumarin-4-yl)-Ala-OH 
(compound 4) was dissolved in a 1:1 (v/v) diethylamine : CH2Cl2 solution at room 
temperature for 3 h under stirring to remove Fmoc protection group.  Compound 2 was 
purified by HPLC (Table 2–1,Table 2–2), confirmed by MALDI-TOF MS (Table 2–3), 
and dried down.  It was then mixed with an approximately stoichiometric amount of 
compound 2 in 2 mL of sodium phosphate buffer as described before, and the reaction was 
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proceeded at room temperature for 2 h.  Biotin~µ was purified by HPLC (Table 2–1,Table 
2–2) and confirmed by MALDI-TOF MS (Table 2–3). 
 
Figure 2–8.  Synthetic Routes of Biotin~FSaa and Biotin~µ.   
 
Fluorescence Spectroscopy  Steady-state fluorescence measurements were acquired 
on a Tecan M1000 plate reader (San Jose, CA, USA), a Varian Cary Eclipse fluorescence 
spectrophotometer (currently Agilent Technologies), or a Photon Technologies 
International (PTI) QuantaMaster™ fluorometer (Birmingham, NJ, USA) fitted with a 
Peltier multicell holder.  For the plate reader, the fluorescence kinetics were collected with 
black 96-well plates with clear bottoms (Greiner Bio-One No. 675096; Frickenhausen, 
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Germany), with an excitation wavelength of 330 nm and emission wavelength of 385 nm 
with 5 nm slit widths and a 400 Hz flash frequency.  For the fluorometers, the fluorescence 
kinetics were collected in 1.00 cm quartz cuvettes, with an excitation wavelength of 325 
nm and the slit width of 5 nm, and an emission wavelength of 391 nm and the slit width of 
5 nm.  The averaging time was 0.100 s.  Peptide concentrations were determined by 
coumarin absorbance at 325 nm243 with an extinction coefficient of 12,000 M-1•cm-1.  
Steady State Protease Assays  Reaction conditions for each protease are listed in 
Table 2–4.  Three independent trials were performed for each assay to ensure 
reproducibility (Figure 2–9). 
Table 2–4.  Steady State Reaction Conditions.   
 
Protease Peptide Buffer Temperature 
0.2 mg/mL 
Chymotrypsin 
8.3 μM 
ASAFAμ / AAFAμ 
100 mM Tris-HCl, pH 7.8 30 °C 
2.5 μg/mL 
Papain 
8.3 μM 
LSLKAAμ / LLKAAμ 
2.0 mM EDTA, 5.00 mM L-
cysteine, 300 mM NaCl, pH 6.2 
25 °C 
1.5 mg/mL 
Pepsin 
0.5 μM 
ASAFAμ / AAFAμ 
10 mM HCl 37 °C 
6 μg/mL 
Thermolysin 
8.3 μM 
ASAFAμ / AAFAμ 
2 mM calcium acetate,  
10 mM sodium acetate, pH 7.5 
25 °C 
25 μg/mL 
Trypsin 
8.3 μM 
LSLKAAμ / LLKAAμ 
67 mM sodium phosphate, pH 7.6 25 °C 
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Figure 2–9.  Triplicates of Steady State Protease Assays.   
 
Three independent trials for each protease are shown as open circles, thin lines, and thick lines.  
Red trace: thiopeptide in the presence of protease; Orange race: thiopeptide in the absence of 
protease; Green trace: corresponding oxopeptide in the presence of protease; Blue trace: 
corresponding oxopeptide in the absence of protease. 
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Heat-Deactivated Enzyme Assay  A sample of papain was heated at 95 °C for 10 
min to abolish the papain activity.  This heat-deactivated papain was tested with thiopeptide 
LSLKAAμ following the previously described steady state papain assay, along with normal 
active papain and all control runs.  No fluorescence change was observed when the 
thiopeptide LSLKAAμ was incubated with the heat-deactivated papain (Figure 2–10). 
 
Figure 2–10.  Heat-Deactivated Papain Assay.   
 
Grey trace: thiopeptide LSLKAAμ in the presence of heat-deactive papain; Red trace: thiopeptide 
LSLKAAμ in the presence of active papain; Orange race: thiopeptide LSLKAAμ in the absence of 
papain; Green trace: oxopeptide LLKAAμ in the presence of active papain; Blue trace: oxopeptide 
LLKAAμ in the absence of papain. 
 
Papain HPLC Assay  26.7 μM LSLKAAμ or LLKAAμ was incubated in in 2.0 mM 
EDTA, 5.00 mM L-cysteine, 300 mM NaCl, pH 6.2 at 25 °C in the presence and absence 
of 3.75 μg/mL papain for different time periods.  At 10 min and 100 min, 200 μL of reaction 
sample was quenched by addition of 800 μL of acetone, then cooled at -20 °C for 1 h to 
precipitate the enzyme.  The sample was then centrifuged at 13,200 rpm at 4 °C for 20 min, 
and the supernatant was separated then dried down first by overnight evaporation of 
acetone and then in a vacuum centrifuge.  Each sample was brought up in 1 mL of H2O 
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and analyzed by HPLC with a Phenomenex Luna C8(2) analytical column (Torrance, CA, 
USA) using gradient 7 (Table 2–2).  MALDI-TOF MS was used to confirm the identity of 
peaks.  Control samples, buffer only or enzyme only solutions without peptides, were 
prepared and analyzed in a similar way. The HPLC signal of control samples was 
subtracted from all other samples to generate the following chromatograms (Figure 2–11). 
 
Figure 2–11.  HPLC Analysis of Papain Cleavage of LSLKAAμ and LLKAAμ.   
 
Blue trace: Signal at 277 nm; Red trace: Signal at 325 nm.  Square: Intact peptide LLKAAμ; Dot: 
Intact peptide LSLKAAμ; Star: Cleaved product AAμ; Triangle: Cleaved product LSLK.  Observed 
[M+H]+ results were labeled under corresponding peptides. 
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Substrate Specificity Assay  To examine substrate specificity, papain steady state 
assay was repeated with ASAFAμ and AAFAμ peptides, which are not expected to be 
cleaved by papain, who specifically recognizes Lys or Arg residues244.  No evidence of 
proteolysis was observed (Figure 2–12). 
 
Figure 2–12.  Substrate Specificity Assay.   
 
Red trace: thiopeptide ASAFAμ in the presence of active papain; Orange race: thiopeptide ASAFAμ 
in the absence of papain; Green trace: oxopeptide AAFAμ in the presence of active papain; Blue 
trace: oxopeptide AAFAμ in the absence of papain. 
 
Papain Kinetics by Stopped-Flow  Papain kinetics were collected with a KinTek SF-
120 instrument (KinTek Corporation; Austin, TX, USA).  Various concentration of 
LSLKAAμ or LLKAAμ was mixed with 1 μg/mL of papain in 2.0 mM EDTA, 5 mM L-
cysteine, 300 mM NaCl, pH 6.2.  Fluorescence signal was collected for 2 min at a rate of 
5,000 points/min, with an excitation wavelength of 310 nm, and the integrated emission of 
wavelengths > 320 nm.  The average of three independent trials for each concentration was 
calculated for data analysis. 
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Papain Kinetics Data Analysis  To determine the concentration of cleaved 
thiopeptides from stopped-flow fluorescence measurements, a separate experiment was 
conducted to reveal a linear relationship between the mole fraction(χ) of LLKAAμ in 
LSLKAAμ / LLKAAμ mixture and fluorescence intensity (Figure 2–13).  The fluorescence 
of LSLKAAμ, LLKAAμ and various LSLKAAμ / LLKAAμ mixtures at the same total 
concentration were collected, and normalized to the LLKAAμ fluorescence. 
 
Figure 2–13.  LLKAAμ Fluorescence.   
 
Error bars are shown as standard error. 
 
The normalized fluorescence F was fit to a linear equation as a function of the mole 
fraction(χ) of LLKAAμ: 
     (2.1) 
Because the fluorescence of cleaved thiopeptide is identical to LLKAAμ, the mole 
fraction of cleaved thiopeptide (χthio) in each reaction could be calculated with equation 2.2. 
χ43955.056045.0 F
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    (S2) 
where F is the measured fluorescence at any given time point t, F0 is the fluorescence 
of the intact thiopeptide.  F0 was determined by extrapolating the y-intercept from linear 
regressions of the first 2 s of measured fluorescence for each reaction.  The concentration 
of cleaved peptide was calculated by multiplying the initial thiopeptide concentration by 
χthio. 
Papain proteolysis can be described by a three-step mechanistic scheme (Figure 2–3, 
Top).  If we assume that the initial formation of enzyme-substrate complex (ES) would 
reach rapid equilibrium following equation 2.3, then the papain kinetics can be described 
by equation 2.4, where [E]0 is the total enzyme concentration, and the instantaneous 
substrate concentration [S] at time t was taken to be approximately equal to the initial 
substrate concentration [S]0
245. 
    (2.3) 
  (2.4) 
In equation 2.4, KM,app is defined with equation 2.5 and kcat is given by equation 2.6. 
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     (2.6) 
The papain kinetics data were globally fit to equation 2.4 (Figure 2–14) using the 
Solver data analysis package in Excel while treating the total active enzyme concentration 
[E]0, the equilibrium constant KS, and the rate constants k2 and k3 as adjustable parameters.  
From this global fit, following kinetic parameters were determined: [E]0 = 1.07 μM, KS = 
921 μM, k2 = 0.92 s-1, k3 = 0.057 s-1, kcat = 0.054 s-1, and KM,app = 53.9 μM. 
A different method was used to generate the Michaelis-Menten plot shown in Figure 
2–3.  The initial rates for each reaction were determined by extrapolating the slopes from 
linear regressions of the first 2 s of product concentration change for each reaction, and 
then fit to equation 2.7 with KaleidaGraph (Synergy Software; Reading, PA, USA).  From 
the fitting, kcat = 0.057 ± 0.001 s
-1 and KM,app = 50.2 ± 1.1 μM were obtained, and they are 
nearly identical to those obtained from global fitting. 
     (2.7) 
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Figure 2–14.  Global Fit of Papain Stopped-Flow Data.   
 
Initial substrate concentration [S]0 is labeled at each figure. 
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Duel-Site Substrate Specificity Assay  Peptides AKGLSAAFAμ and AKGLAAFAμ 
were prepared so that they were able to be cleaved by both chymotrypsin and trypsin.  
Steady state assays of 8.3 μM peptides with 5 μg/mL chymotrypsin, 25 μg/mL technical 
grade trypsin, or 1 μg/mL sequencing-grade modified trypsin (Promega; Madison, WI, 
USA) were conducted as previously described.  When technical grade trypsin was mixed 
with AKGLSAAFAμ, a slight increase in fluorescence was observed (Figure 2–15).  This 
observation was attributed to chymotrypsin impurity in the technical grade trypsin, as 
indicated by the manufacture, and was not observed with the sequencing grade trypsin. 
 
Figure 2–15.  Technical Grade Trypsin Assay.   
 
Red trace: thiopeptide AKGLSAAFAμ in the presence of trypsin; Orange race: thiopeptide 
AKGLSAAFAμ in the absence of trypsin; Green trace: oxopeptide AKGLAAFAμ in the presence of 
trypsin; Blue trace: oxopeptide AKGLAAFAμ in the absence of trypsin. 
 
HPLC analysis of each reaction was performed according to the same procedure 
described earlier.  120 μL of each reaction was quenched by addition of 1080 μL cold 
ethanol to precipitate the protease, at 1 h for chymotrypsin or 2 h for trypsin. 
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Figure 2–16.  HPLC Analysis of Dual-Site Substrate.   
 
Blue trace: Signal at 277 nm; Red trace: Signal at 325 nm.  Square: Intact peptide AKGLAAFAμ; 
Dot: Intact peptide AKGLSAAFAμ; Star: Cleaved product GLAAFAμ; Triangle: Cleaved product 
GLSAAFAμ; Diamond: Cleaved product Aμ; Double dagger: Cleaved product AKGLSAAF.  
Observed [M+H]+ results were labeled under corresponding peptides. 
 
Thioamide Stability in Solvent  A sample of 100 µL crude ASAFAµ in H2O/CH3CN 
(1:2 v/v) was analyzed by HPLC immediately after cleavage off the resin using gradient 
described earlier (Table 2–2).  Another sample of the same crude was stored at 4 °C for 
454 days, and then analyzed by HPLC.  No difference was observed between the two 
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samples based on the chromatograms and MALDI-TOF MS characterization of the major 
peak as ASAFAµ. 
 
Figure 2–17.  Stability of ASAFAµ in H2O/CH3CN Solution.   
 
Absorbance was monitored at 277 nm. 
 
Thiopeptide Stability in PBS and Mouse Serum  Thioeptide Biotin~FSaa 
(compound 3) were incubated in PBS buffer (10 mM Na2HPO4, 150 mM NaCl, pH 7.00) 
or mouse serum at 37 °C to test its stability.  A stock solution of 70.5 µM Biotin~FSaa and 
94.3 µM Biotin~µ, as internal standard, in H2O was prepared.  70 μL of the stock solution 
were added to 280 μL of PBS buffer or mouse serum, then incubated in a 37 °C water bath 
for 1 h, 4 h, or 24 h time periods.  70 μL of the stock solution were brought up in 280 μL 
H2O to serve as 0 h sample.  All these samples were loaded onto 400 μL of immobilized 
neutravadin resin, and incubated at room temperature for 10 min.  10 column volumes 
(CVs) of PBS were used to wash the resin after incubation.  1 mL of 50 mM DTT was 
added to the resin and allowed to incubate at room temperature for 30 min to cleave 
peptides off biotin handles.  The flow through was collected and analyzed by HPLC using 
gradient 2 with a Vydac 218TP C18 analytical column (Figure 2–18, Right).  Peaks were 
identified by MALDI-TOF MS (Table 2–5).  Three independent trials were conducted for 
  
93 
 
 
 
each reaction to ensure reproducibility.  To quantify peptides, peak areas were calculated 
at 270 nm for ~FSaa and 325 nm for ~µ, and the ~FSaa signal was normalized to that of ~µ 
in each trial.  The average ratio of three independent trials were calculated.  The ratio of 0 
h was assigned as 100, and all other samples were standardized to 0 h sample (Figure 2–
18, Up Left).  No loss of FSaa was observed in PBS after 1 h, and only 5 % loss after 24 h.  
15 % loss of FSaa was observed in mouse serum after 1 h, and 20 % loss after 4 h. 
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Figure 2–18.  Thiopeptide Stability in PBS and Mouse Serum.   
 
A)  Amount of thiopeptide ~FSaa recovered after incubation in PBS or mouse serum.  B)  Chemical 
structures of compound 7 (~μ) and compound 8 (~FSaa), and calculated masses.  C)  
Representative HPLC traces of each trial.  Red trace: Absorbance at 325 nm; Blue trace: 
Absorbance at 277 nm.  Square: Peak of ~μ; Circle: Peak of ~FSaa. 
 
Table 2–5.  Calculated and Observed Peptide Masses.   
 
Peptide 
[M+H]+ [M+Na]+ [M+K]+ 
Calculated Observed Calculated Observed Calculated Observed 
~FSaa 352.09 351.98 374.07 373.96 - - 
~μ - - 434.12 434.02 450.09 450.00 
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Purified Calpain Steady State Assay  8 µM of LSPLFAERμ or LPLFAERμ was 
mixed with 25 nM calpain 1 in calpain buffer (10 mM dithioreitol, 5 mM KH2PO4, 2 mM 
EGTA, and 0.015% Brij-35, pH 7.5)216, 246.  Calpain was activated by adding 10 mM CaCl2 
to the mixture, and calpain buffer was added instead of CaCl2 in the negative control.  
Time-course fluorescence was monitored by the Tecan plate reader using protocol 
described earlier.  A fluorescence increase was only observed in the presence of Ca2+ with 
thiopeptide (Figure 2–19). 
 
Figure 2–19.  Purified Calpain Steady State Assay.   
 
Red trace: thiopeptide LSPLFAERμ in the presence of Ca2+; Orange race: thiopeptide LSPLFAERμ 
in the absence of Ca2+; Green trace: oxopeptide LPLFAERμ in the presence of Ca2+; Blue trace: 
oxopeptide LPLFAERμ in the absence of Ca2+. 
 
Calpain Cell Lysate Assay  MEF cells were cultured in DMEM supplemented with 
10 % fetal bovine serum and 1:100 penicillin and streptomycin at 37 ˚C (Gibco, Life 
Technologies, Grand Island, NY, USA) until 90 % confluency then trypsinized, pelleted, 
and frozen.  The frozen cells were lysed using freeze-thaw method in hypotonic lysis buffer 
(10 mM dithiothreitol, 5 mM KH2PO4, and 6 mM EGTA, pH 7.5)
247.  Total protein 
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centration of the cell lysate was determined by bicinchoninic acid assay (Thermo 
Scientific/Pierce; Rockford, IL, USA) as ~ 4 mg/mL248.  8 µM of LSPLFAERµ or 
LPLFAERµ was added into cell lysates with 25 µM of calpain inhibitor or no inhibitor.  
Calpains in cell lysates were activated by additional 10 mM of CaCl2.  Time-course 
fluorescence was monitored by the Tecan plate reader using protocol described earlier. 
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Chapter 3 .  Positional Effects of Thioamide On Protease Activity 
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3.1  Introduction 
Several previous reports have indicated that a thioamide at the scissile bond of 
protease substrates can suppress proteolysis, so when we designed our fluorescent probes, 
the thioamide was placed away from the scissile bond.  Indeed, our previous study showed 
that a thioamide at the P3 position did not impact the cleavage rate of papain compared to 
the corresponding oxoamide peptide.  However, this specific case may not represent a 
general principle.  Therefore, we wished to rigorously test the positional effects of 
thioamides on the activity of a variety of proteases.  Completion of our studies will allow 
us to provide more general guidance on where to place a non-perturbing thioamide in the 
substrate to design optimal probes for different types of cleavage events.  In addition, this 
will inform us as to whether a thioamide near the scissile bond will be disruptive to 
proteolysis, and could therefore serve as a general strategy to stabilize peptide therapeutics 
against proteolytic degradation.  Importantly, we designed a systematic approach that 
should provide insight as to mechanism. 
We wished to test representative proteases from the four major classes.  The effect of 
the thioamide substitution is likely to vary depending on the protease mechanism.  For 
cysteine proteases and serine proteases, the thioamide may disrupt the oxyanion hole 
stabilization of the tetrahedral intermediates that is essential to catalysis.  For 
metalloproteases, a thioamide at the P2 or P1' position might hinder proteolysis via metal 
chelation.  For aspartic acid proteases, water attack on the scissile bond may be altered 
because of the presence of thioamide, which is effectively more hydrophobic than an 
oxoamide.  Specifically, we tested papain as a representative cysteine protease, trypsin and 
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chymotrypsin as serine proteases, thermolysin as a metalloprotease, and pepsin as an 
aspartic protease.   
To quickly and easily assess the positional effects of thioamide on proteolysis, we took 
advantage of our newly developed thioamide-based fluorescent protease probe system.  A 
thioamide can be placed at the position to be tested, along with a fluorophore on the other 
side of the scissile bond so that a fluorescence increase will be observed upon proteolysis.  
In order to investigate the positions at both sides of the scissile bond, we designed the probe 
to be labelled with a 7-methoxycoumarin-4-yl-alanine (Mcm; µ) fluorophore at both ends 
(Figure 3–1).  With this design, no matter where the thioamide is located, either on the 
primed side or the non-primed sides in the substrate, one fluorophore will be separated 
from the thioamide once the substrate is cleaved, thus the proteolysis can be monitored by 
a fluorescence change.  The amino acid sequence of the probes would be selected to be 
best recognized by the target proteases. 
 
Figure 3–1.  Design of Thioamide Positional Scanning Probes.   
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The thioamide was scanned from P3 to P3' positions in the substrate, and compared to 
the corresponding oxoamide substrate for kinetic analysis.  We also tried to understand the 
mechanism of the proteolytic resistance from thioamides.  For the positions where we 
observed significant inhibition, we conducted full concentration dependent studies to 
determine the kcat and KM of the thiopeptide, as well as the comparison of these kinetic 
parameters to the oxoamide peptides.  Assessment of whether the stabilized thioamides can 
serve as inhibitors of other substrates was performed to study the mechanism of 
stabilization. 
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3.2  Results and Discussion 
We began by synthesizing all the peptides labeled with Mcm at both N-terminus and 
C-terminus, and a thioamide scanned through all the other positions.  Two series of 
peptides were prepared such that they would be cleaved by a variety of proteases: 
μLLKAAAμ and its thioamide analogs would be recognized by papain and trypsin; 
μKAAFAAAμ and its thioamide analogs would be recognized by chymotrypsin, pepsin 
and thermolysin.  In addition, μLLRAAAμ and μLLRSAAAμ were also synthesized for 
papain and trypsin to further test the effect of amino acid sidechain at the scissile bond. 
In a typical experiment, the fluorescence of the peptide in the presence and absence of 
a protease was monitored as a function of time.  The concentrations of peptide and protease 
were chosen so that the proteolysis of the non-modified oxoamide probe would reach 
completion within 30 min.  Depending on the position of thioamides, the fluorescence of 
intact thiopeptides were quenched from 75 % to 50 % relative to the corresponding intact 
oxoamide peptide (Figure 3–6, Figure 3–9, Figure 3–10).  Generally, the closer the 
thioamide was to one fluorophore, the more quenching was observed.  In the absence of 
protease, the fluorescence of all peptides remained relatively constant, with slight decreases 
presumably due to photobleaching.  Upon addition of protease, an immediate fluorescence 
increase was observed for both oxoamide control peptides and thioamide-modified 
peptides.  For oxopeptides, the fluorescence increase comes from the release of self-
quenching effects of the two Mcm fluorophores.  For thiopeptides, the source of the 
fluorescence increase is complicated, but we can view it as the release of a combination of 
Mcm self-quenching and the quenching due to the thioamide on the opposite side of the 
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scissile bond.  Regardless of the photophysical mechanism, the fluorescence change could 
be analyzed to reflect the proteolysis kinetics.  From kinetic analysis, the half-life of each 
peptide with each protease was obtained for comparison of thioamide effects. 
For trypsin proteolysis, the effects of a thioamide at position P3 to P3' were examined 
as compared to the corresponding oxoamide peptide (Table 3–1, Figure 3–6, Figure 3–7).  
A large increase in half-life was observed when the thioamide is at the scissile bond, 
regardless of whether the P1 sidechain was Lys or Arg, showing that this is not a special 
case with a particular sequence.  However, the half-life increase was more dramatic for 
ArgS ( > 1000-fold) at the scissile bond compared to a LysS (66-fold) at the scissile bond.  
For thioamides at all the other positions, small perturbations to the proteolysis were 
observed with a 1.5 – 5 fold increase in half-life.   
Table 3–1.  Half-lives of Peptides Cleaved by Trypsin.   
 
Thioamide Position Substrate Trypsin t1/2 (min) 
Oxoamide Control μLLKAAAμ 01.02 ± 0.04 
Oxoamide Control μLLRAAAμ 00.12 ± 0.02 
P3 μLSLKAAAμ 04.38 ± 0.06 
P2 μLLSKAAAμ 01.56 ± 0.04 
P1 μLLKSAAAμ 67.14 ± 0.52 
P1 μLLRSAAAμ > 125 
P1' μLLKASAAμ 05.02 ± 0.95 
P2' μLLKAASAμ 03.95 ± 0.06 
P3' μLLKAAASμ 03.89 ± 0.03 
 
To help us understand the basis for the enormous effect of P1 thioamide substitution, 
we consulted previous structural studies of the trypsin active site.  In the crystal structure 
of trypsin bound to bovine pancreatic trypsin inhibitor, only the amide bond at the P1 
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position of the inhibitor has a significant hydrogen bonding acceptor role (Figure 3–2)249.  
The P2 carbonyl does make a hydrogen bond with the Gln192 sidechain, but this is a 
presumably flexible interaction that could tolerate the longer thiocarbonyl.  In contrast, the 
P1 position features a bifurcated hydrogen bond with the backbone amide N–H groups of 
Asp194 and Ser195, the so-called oxyanion hole.  With a longer C=S bond length and poorer 
hydrogen bond acceptor ability, it is possible that the thiopeptide can no longer bind to 
trypsin tightly, or that interaction with the oxyanion hole is disrupted such that the 
tetrahedral intermediate cannot be stabilized efficiently, leading to decreased turnover rate.  
In an earlier study, Cho observed similar resistance to trypsin with a thioamide at the P1 
position, which the author attributed to oxyanion hole destabilization199.   
 
Figure 3–2.  Crystal Structure of Trypsin Bound with Bovine Pancreatic Trypsin Inhibitor (BPTI).   
 
Trypsin structure is shown in green, and BPTI structure is shown in cyan.  BPTI residue positions 
are labelled in the figure.  The carbonyl oxygens at the P1 and P2 positions are shown in yellow 
and red spheres.  Hydrogen bonding interactions between trypsin and the BPTI are shown in dotted 
lines.  Adapted from Marquart et al. (PDB ID: 1TPA)249. 
 
  
104 
 
 
 
In order to determine whether the P1 thiopeptides were binding, but not productively 
proteolyzed, we studied their ability to act as competitive inhibitors of trypsin.  We tested 
whether μLLKSAAAμ and μLLRSAAAμ would inhibit proteolysis of a commercially 
available trypsin probe, N-Benzoyl-L-Arginine-4-nitroanilide (Figure 3–12, Table 3–8).  
No significant differences were observed in kcat/KM of the reaction in the presence or 
absence of 1 μM or 10 μM of either thiopeptide, indicating that thiopeptides do not act as 
effective trypsin inhibitors (a small decrease in kcat/KM was observed with 10 µM 
μLLRSAAAμ).  Indeed, even a 100 µM concentration of the thiopeptide did not 
significantly inhibit proteolysis rates (although full kcat/KM determinations were not made).  
This result indicates that the primary effect of the thioamide is not to disrupt oxyanion hole 
interactions of the tetrahedral intermediate, but to weaken binding to the protease. 
With papain, different positional effects were observed when a thioamide was scanned 
from P3 to P3' using the same peptides (Table 3–2, Figure 3–9, Figure 3–8).  Placement 
of the thioamide at the scissile bond affected the rate of papain proteolysis slightly with a 
2-fold increase in half-life, in stark contrast to the enormous effects seen with trypsin.  A 
similar result was observed by Cho, where a thioamide at the scissile bond slowed down 
papain proteolysis only slightly199.  More dramatic effects were observed for the thioamide 
at the P2 or P1' positions than the P1 position, with an at least 12-fold increase in half-lives.  
For peptides with a thioamide at the P3, P2' or P3' positions, their half-lives were almost 
identical to the oxoamide half-life. 
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Table 3–2.  Half-lives of Peptides Cleaved by Papain.  
 
Thioamide Position Substrate Papain t1/2 (min) 
Oxoamide Control μLLKAAAμ 04.81 ± 0.10 
Oxoamide Control μLLRAAAμ 05.04 ± 0.08 
P3 μLSLKAAAμ 04.38 ± 0.08 
P2 μLLSKAAAμ > 60 
P1 μLLRSAAAμ 11.54 ± 0.08 
P1' μLLKASAAμ > 60 
P2' μLLKAASAμ 04.87 ± 0.05 
P3' μLLKAAASμ 05.01 ± 0.07 
 
As with trypsin, we used existing crystal structures to help us to interpret these results.  
Inspection of a papain structure with a covalently-bound inhibitor (a chloromethyl ketone 
reacted with the active site Cys) reveals that the amide carbonyl O at the P2 position makes 
a bifurcated H-bond with the protein backbone, which might be perturbed by thionation, 
while the P1 amide makes no significant hydrogen bonding (Figure 3–3)250.  Unfortunately, 
no appropriate structure exists to aid in interpretation of the P1' effect of papain.  Although 
the thioamide at the P2 or P1' position both suppressed papain proteolysis, they may 
originate from different mechanisms, since they displayed different kinetics patterns.  
Specifically, the reaction with the thioamide at the P1' position was biphasic, clearly 
showing a burst phase at the beginning of the reaction (Figure 3–9).  This may indicate 
that after the rapid formation of the acyl-enzyme intermediate, the intermediate is more 
difficult to hydrolyze, or the hydrolyzed non-primed side of the substrate with a thioamide 
remains bound in the active site.  On the other hand, the reaction with the thioamide at the 
P2 position showed monoexponential kinetics over the timescale of reaction monitoring. 
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Figure 3–3.  Crystal Structure of Papain Bound with Suicide Inhibitor.   
 
Papain structure is shown in lavender, and the suicide inhibitor (Acetyl-L-alanyl-L-alanyl-L-
phenylalanyl-L-alanine chloromethyl ketone) structure is shown in orange.  The inhibitor residue 
positions are labelled in the figure.  The carbonyl oxygen at the P2 position is shown in yellow 
sphere.  Hydrogen bonding interactions between papain and the inhibitor P2 carbonyl oxygen are 
shown in dotted lines.  Adapted from Drenth et al. (PDB ID 1PAD)250. 
 
Chymotrypsin was also tested to be compared with trypsin.  Both are serine proteases 
with nearly identical overall structures and catalytic mechanisms, but different preferences 
for substrates.  Chymotrypsin cleaves after aromatic residues, so we prepared the sequence 
μKAAFAAAμ for it.  The oxoamide control peptide and peptides with thioamide at 
positions P4 to P1 and P2' were examined (Table 3–3, Figure 3–10).  Due to solubility 
problem, we were unable to determine the half-life of the oxoamide control peptide.  
Because the P4 position is far away from the scissile bond, we believe that the substrate 
with a thioamide at the P4 position can be representative of the oxoamide proteolysis rate, 
and used to normalize the other thiopeptide data.  Similar to the trypsin experiments, the 
thioamide at the scissile bond greatly inhibited chymotrypsin proteolysis with an at least 
100-fold increase in half-life.  The thioamide at the P3 position had a slightly increased 
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half-life (3-folds increase) compared to the control peptide, and thioamide at the P2' 
position was almost identical to the control peptide.  All of these findings are consistent 
with our observations with trypsin.  In contrast, we found that thioamide at the P2 position 
also significantly inhibited chymotrypsin proteolysis, with a biphasic kinetic pattern 
(Figure 3–10). 
Table 3–3.  Half-lives of Peptides Cleaved by Chymotrypsin.   
 
Thioamide Position Substrate Chymotrypsin t1/2 (min) 
P4 μKSAAFAAAμ 0.37 ± 0.01 
P3 μKASAFAAAμ 1.19 ± 0.02 
P2 μKAASFAAAμ > 40 
P1 μKAAFSAAAμ > 40 
P2' μKAAFAASAμ 0.46 ± 0.04 
 
In general, when thioamides were placed away from the scissile bond in the substrate, 
beyond the P2 position on the primed side and beyond the P1' position on the non-primed 
side, at most slight perturbations were observed.  These positions would be suitable for 
thioamide incorporation for the purpose of monitoring protease activity without altering 
the protease behaviors.  For the scissile bond and positions close to the scissile bond, the 
P2 to P1' positions, a thioamide at these positions is likely to be disruptive to proteolysis 
and may serve to enhance the resistance of the substrate against proteolysis.   
Although general trends are observed, these experiments also clearly showed that 
thioamide effects depend on both the peptide sequence and the protease, arising from 
effects on binding, catalysis, or turnover.  However, with an aid of crystal structures 
showing the interactions between the protease and its substrate, it may be possible to 
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predict which positions interfere with protease catalysis and which do not.  The data to date 
indicate that while disruption of some hydrogen bond acceptor functions in the substrate 
are tolerated, bifurcated hydrogen bond pockets cannot tolerate the increased size of the 
thiocarbonyl. 
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3.3  Conclusion 
We have systematically investigated the positional effects of thioamide substitution in 
substrates on protease catalysis, and identified positions suitable for different purposes of 
thioamide incorporation.  For trypsin, the scissile bond is the only position where 
thioamides have a significant impact on protease activity.  The best position for a thioamide 
to generate a non-perturbing protease probe would be the P2 position.  For papain, 
significant suppression of proteolysis occurs with thioamide substitutions at the P2 or P1' 
positions.  At positions beyond P2 and P1', thioamide incorporation does not interfere with 
protease activity and can be used in probe design.  For chymotrypsin, both the P2 and P1 
positions are suitable for greatly extending the half-life of the substrates against proteolysis 
with thioamide substitutions, while a thioamide at the P2' position does not perturb protease 
activity at all.  While more mechanistic study is clearly warranted, our experiments thus 
far indicate that these effects result from compromised binding to the protease rather than 
from interference in the chemical steps of the mechanism.  In conclusion, from our 
systematic investigation of thioamide positional effect on proteolysis, thioamides far away 
from the scissile bond do not disrupt protease activity while thioamides near or at the 
scissile bond exhibited different levels of resistance to proteolysis.  This further 
demonstrated that thioamide can be employed to design non-disruptive protease activity 
probes at positions away from the scissile bond, and provided evidence of using thioamide 
near the scissile bond as a peptide stabilization strategy against proteolysis.   
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3.4  Future Directions 
In order to understand the positional effects of thioamide substitution more thoroughly, 
we would like to test more proteases.  Specifically, thermolysin will be tested as 
representative metalloprotease, and pepsin will be tested as representative aspartic protease.  
To examine whether the effects for a particular protease is dependent on the substrate 
sequence, a second sequence should also be tested for each protease.  More rigorous kinetic 
studies should be performed to understand the mechanisms of perturbation of proteolysis 
from thioamide substitution.  For the substrates showing extended half-lives, the kcat and 
KM should be determined and compared to these of the corresponding oxoamide control 
substrates to elucidate the origin of the inhibition.  These substrates would also be 
examined to see whether they could serve as protease inhibitors.  Finally, we would like to 
combine the results from our experimental studies with computational studies to design a 
program to predict thioamide effects and design stabilized peptides.   
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3.5  Materials and Methods 
General Information  Fmoc-β-(7-methoxycoumarin-4-yl)-Ala-OH were purchased 
from Bachem (Torrance, CA, USA).  All other Fmoc protected amino acids and 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were 
purchased from Novabiochem (currently EMD Millipore; Billerica, MA, USA).  Piperidine 
was purchased from American Bioanalytical (Natick, MA, USA).  Sigmacote®, N,N-
diisopropylethylamine (DIPEA), N-benzoyl-L-arginine 4-nitroanilide, trypsin (lyophilized 
powder; from porcine pancreas; Type II-S; 1,000 – 2,000 units/mg dry solid), thermolysin 
(lyophilized powder; from Geobacillus stearothermophilus; 30 – 175 units/mg protein), 
papain (crude powder; from papaya latex; 1.5 – 10 units/mg solid), and pepsin (lyophilized 
powder; from porcine gastric mucosa; 3,200 – 4,500  units/mg protein) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).  Chymotrypsin (lyophilized powder; from 
Bovine Pancreas, ≥ 40 units/mg protein) was purchased from MP Biomedicals (Santa Ana, 
CA, USA).  All other reagents were purchased from Fisher Scientific (Pittsburgh, PA, USA) 
unless specified otherwise.  Milli-Q filtered (18 MΩ) water was used for all solutions 
(EMD Millipore).  Time-course UV-Vis absorbance and fluorescence were obtained with 
a Tecan Infinite® M1000 PRO plate reader (San Jose, CA, USA).  Peptides were purified 
with a Varian ProStar High-Performance Liquid Chromatography (HPLC) with a diode 
array detector (currently Agilent Technologies), and analyzed with an Agilent 1100 Series 
HPLC system.  Peptide mass spectrometry were collected with a Bruker Ultraflex III 
MALDI-TOF-TOF mass spectrometer (Billerica, MA, USA). Nuclear magnetic resonance 
(NMR) spectra were collected with a Bruker DMX 500 MHz instrument (Billerica, MA).  
  
112 
 
 
 
High resolution electrospray ionization mass spectra (ESI-HRMS) were obtained on a 
Waters LCT Premier XE liquid chromatograph/mass spectrometer (Milford, MA).  Low 
resolution electrospray ionization mass spectra (ESI-LRMS) were obtained on a Waters 
Acquity Ultra Performance LC connected to a single quadrupole detector mass 
spectrometer. 
 
Figure 3–4.  Synthesis Scheme of Thioarginine Precursors.   
 
Synthesis of Nα-Fmoc-Nω-Pbf-L-arginine-2-amino-5-nitroanilide (1)  Under argon 
atmosphere, Fmoc-Arg(Pbf)-OH (3.2439 g, 5 mmol, 1 equiv.) was dissolved in 50 mL of 
dry tetrahydrofuran (THF) and equilibrated to -10 °C in a salt ice bath (NaCl : ice = 1:3).  
Under magnetic stirring, N-methylmorpholine (NMM, 1.10 mL, 10 mmol, 2 equiv.) and 
isobutylchloroformate (IBCF, 0.65 mL, 5 mmol, 1 equiv.) were added to the solution 
dropwise by a syringe.  The reaction was allowed to proceed for 15 min at -10 °C with 
stirring.  4-nitro-1,2-pheylenediamine (0.7657g, 5 mmol, 1 equiv.) was added and the 
reaction was stirred at -10 °C for 2 h, then at room temperature overnight.  After removal 
of solvent by rotary evaporation, the residue was dissolved in 40 mL of ethyl acetate, and 
extracted against 40 mL each of 1 M Na2HPO4, brine, 5% NaHCO3, and brine.  The 
aqueous layers were combined and extracted against 100 mL of ethyl acetate.  All the 
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organic layers were combined, and the solvent was removed by rotary evaporation.  An 
orange foam was obtained as the final product (3.3985 g, 4.335 mmol, 86.7% yield) in 75% 
purity (determined by HPLC).  Rf = 0.51 in 9:1 ethyl acetate : petroleum ether.  ESI
+-
LRMS: m/z calculated for C40H46N7O8S [M+H]
+ 784.31, found 784.57. 
Synthesis of Nα-Fmoc-Nω-Pbf-L-thioarginine-2-amino-5-nitroanilide (2)  
Anhydrous Na2CO3 (0.1590 g, 1.5 mmol, 0.75 equiv.) and P4S10 (0.6668 g, 1.5 mmol, 0.75 
equiv.) were dissolved in 20 mL of dry THF and stirred at room temperature under argon 
for 1-2 h until the mixture turned into a clear pale yellow solution.  Compound 1 (1.5678 
g, 2 mmol, 1 equiv.) was added to the solution and allowed to react overnight at room 
temperature under argon atmosphere.  Upon completion, the solvent was removed by rotary 
evaporation.  The crude was purified by flash chromatography in ethyl acetate/petroleum 
ether (9:1 v/v) to yield an orange foam (1.1219g, 1.402 mmol, 70.1 % yield) in 95% purity 
(determined by HPLC).  Rf = 0.24 in 9:1 ethyl acetate : petroleum ether.  ESI
+-LRMS: m/z 
calculated for C40H46N7O7S2 [M+H]
+ 800.29, found 800.50. 
Synthesis of Nα-Fmoc-Nω-Pbf-L-thioarginine-nitrobenzotriazolide (3)  Compound 
2 (1.1999 g, 1.5 mmol, 1 equiv.) was added in 20 mL of 5 % glacial acetic acid in water at 
0 °C until fully dissolved.  With stirring, NaNO2 (0.1553 g, 2.25 mmol, 1.5 equiv.) was 
added in small portions over 5 min.  The reaction was allowed for 30 min at 0 °C, then 
quenched with 75 mL of ice cold water, resulting in an orange precipitate.  The precipitate 
was collected by filtration, rinsed with cold water, and dried on vacuum for 30 min.  An 
orange solid was yielded as the final product (0.8735 g, 1.077 mmol, 71.8% yield) in 80% 
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purity (determined by HPLC).  ESI+-LRMS: m/z calculated for C40H43N8O7S2 [M+H]
+ 
811.27, found 811.49. 
 
Figure 3–5.  Synthesis Scheme of Thiolysine Precursors.   
 
Synthesis of Nα-Fmoc-Nε-Boc-L-lysine-2-amino-5-nitroanilide (4)  Under argon 
atmosphere, Fmoc-Lys(Boc)-OH (2.3412 g, 5 mmol, 1 equiv.) was dissolved in 50 mL of 
anhydrous tetrahydrofuran (THF) and chilled to -10 °C in a salt ice bath (NaCl : ice = 1:3).  
Under magnetic stirring, NMM (1.10 mL, 10 mmol, 2 equiv.) and IBCF (0.65 mL, 5 mmol, 
1 equiv.) were added to the solution dropwise by a syringe.  The reaction was stirred for 
15 min at -10 °C.  4-nitro-1,2-pheylenediamine (0.7657g, 5 mmol, 1 equiv.) was added and 
the reaction was allowed to proceed at -10 °C for 2 h, then at room temperature overnight.  
Upon completion, the solvent was removed by rotary evaporation.  The residue was 
dissolved in 40 mL of ethyl acetate, and extracted against 40 mL each of 1 M Na2HPO4, 
brine, 5% NaHCO3, and brine.  The aqueous layers were combined and extracted against 
100 mL of ethyl acetate.  All the organic layers were combined, and the solvent was 
removed by rotary evaporation.  A red powder was obtained as the final product (3.50 g, 
5.80 mmol, 117% yield) in 70% purity (determined by HPLC). Rf = 0.71 in 95:5 ethyl 
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acetate : petroleum ether.  ESI+-HRMS: m/z calculated for C32H37N5O7 [M+Na]
+ 626.2385, 
found 626.2591. 
Synthesis of Nα-Fmoc-Nε-Boc-L-lysine-2-amino-5-nitroanilide (5)  Anhydrous 
Na2CO3 (0.1590 g, 1.5 mmol, 0.75 equiv.) and P4S10 (0.6668 g, 1.5 mmol, 0.75 equiv.) was 
dissolved in 20 mL of dry THF and stirred at room temperature under argon for 1-2 h until 
the mixture turned into a clear pale yellow solution.  Compound 4 (1.2065 g, 2 mmol, 1 
equiv.) was added to the solution and allowed to react overnight at room temperature under 
argon atmosphere.  Upon completion, the solvent was removed by rotary evaporation.  The 
crude was purified by flash chromatography in ethyl acetate/petroleum ether (4:6 v/v) to 
yield a bright yellow foam (0.4931 g, 0.65 mmol, 32.6% yield) in 87% purity (determined 
by HPLC).  Rf = 0.34 in 45:55 ethyl acetate : petroleum ether; 
1H NMR (500 MHz, CDCl3): 
δ 9.55 (s, 1H), 8.04 (s, 1H), 7.99 (d, J = 11.8 Hz, 1H), 7.74 (dd, , J = 2.4, 7.6 Hz, 2H), 7.55 
(t, J = 7.1 Hz, 2H), 7.37 (q, J = 6.8 Hz, 2H), 7.28 – 7.24(m, 3H), 6.65 (d, J = 9.8 Hz, 1H), 
6.11 (s, 1H), 4.77 (s, 2H), 4.54 (s, 1H), 4.39 (s, 1H), 4.32 (t, J = 8.8 Hz, 1H), 4.17 (t, J = 
7.1 Hz, 1H), 3.15 (s, 2H), 1.93 (d, J = 42.4 Hz, 2H), 1.52 (d, J = 24.7 Hz, 4H), 1.42 (s, 9H). 
ESI+-HRMS: m/z calculated for C32H37N5O6S [M+Na]
+ 642.2357, found 642.2362. 
Synthesis of Nα-Fmoc-Nε-Boc-L-lysine-nitrobenzotriazolide (6)  Compound 5 
(0.3531 g, 0.57 mmol, 1 equiv.) was added in 5 mL of 5 % glacial acetic acid in water at 
0 °C until fully dissolved.  With stirring, NaNO2 (0.0590 g, 0.86 mmol, 1.5 equiv.) was 
added in small portions over 5 min.  The reaction was allowed for 30 min at 0 °C, then 
quenched with 25 mL of ice cold water, resulting in a yellow precipitate.  The precipitate 
was collected by filtration, rinsed with cold water, and dried on vacuum for 30 min.  A 
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yellow solid was yielded as the final product (0.3244 g, 0.5075 mmol, 89.0% yield) in 75% 
purity (determined by HPLC).  Rf = 0.83 in 1:1 ethyl acetate : petroleum ether.  ESI
+-
LRMS: m/z calculated for C32H34N6O6S [M+Na]
+ 653.2153, found 653.2166. 
Peptide Synthesis and Purification  Each peptide was synthesized on a 25 μmol scale 
on 2-chlorotrityl resin manually using our established protocols.  Prior to use, the glass 
peptide reaction vessel (RV) was coated with Sigmacote®, and dried under vacuum.  For 
a typical synthesis, 2-chlorotrityl resin was added to a dry RV, and swelled in 5 mL 
dimethylformamide (DMF) for two successive 30 min with magnetic stirring.  Between 
each reaction, the resin was washed extensively with adequate DMF.  For the first amino 
acid coupling, 5 equiv. of amino acid was dissolved in 1.5 mL of DMF and added to the 
RV, following an addition of 10 equiv. of DIPEA.  The reaction was allowed for 30 min 
under stirring.  After washing, the resin was incubated with 2 mL of 20 % piperidine 
solution in DMF for 20 min under stirring for deprotection.  The same deprotection 
procedure was followed for all the subsequent standard amino acids.  For a typical coupling 
reaction, 5 equiv. of amino acid and 5 equiv. of HBTU was dissolved in DMF, and added 
to the RV, with an addition of 10 equiv. of DIPEA.   
Thioamide was introduced with a slight different coupling and deprotection 
procedures.  Thioamide was coupled through pre-activated precursors.  2 equiv. thioamide 
precursor in 1.5 mL of dry dichloromethane (DCM) was added to the RV with 2 equiv. 
DIPEA, and stirred for 45 min.  For deprotection of thioamides except thiophenylalanine 
(PheS), 20 % piperidine in DMF was added to the RV and allow for successive 5 min and 
15 min incubation with resins under magnetic stirring.  To minimize racemization, PheS 
  
117 
 
 
 
was deprotected with 2 % 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) in DMF for three 
successive 2 min.  All the standard amino acids coupled after PheS were also deprotected 
with 2 % DBU in DMF for three successive 2 min. 
Upon completion of the synthesis, the resin was dried with DCM under vacuum.  
Peptides were cleaved off resin by the treatment of a 3 mL fresh cleavage cocktail of DCM, 
trifluoroacetic acid (TFA), water, and triisopropylsilane (TIPS) (65:30:2.5:2.5 v/v) for two 
successive 30 min on a rotisserie.  After each treatment, the cocktail solution was expelled 
from the RV with nitrogen, reduced to a volume of less than 1 mL by rotary evaporation.  
The crude was stored at -80 °C until purification.  The crude was diluted in CH3CN/H2O 
(1:1 v/v) and then purified on a Vydac 218TP C18 semi-prep column (Grace/Vydac; 
Deerfield, IL, USA) by HPLC using the following gradients (Table 3–4, Table 3–5) at a 
flow rate of 12 mL/min.  MALDI-TOF MS was used to confirm peptide identifies (Table 
3–6).  Purified peptides were dried on a lyophilizer (Labconco; Kansas City, MO, USA) or 
in a vacuum centrifuge (Savant/Thermo Scientific; Rockford, IL, USA).  If needed, 
peptides were subjected to multiple rounds of purification until 99% purity was achieved. 
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Table 3–4.  Peptide Purification Methods and Retention Time.   
 
Peptide Gradient Retention Time 
μLLKAAAμ 1 35 min 
μLSLKAAAμ 1 33 min 
μLLSKAAAμ 1 35 min 
μLLKSAAAμ 1 35 min 
μLLKASAAμ 2 28 min 
μLLKAASAμ 2 28 min 
μLLKAAASμ 2 28 min 
μLLRAAAμ 1 35 min 
μLLRSAAAμ 1 35 min 
μKAAFAAAμ 3 23 min 
μKSAAFAAAμ 4 20 min 
μKASAFAAAμ 4 20 min 
μKAASFAAAμ 4 23 min 
μKAAFSAAAμ 4 22 min 
μKAAFAASAμ 4 33 min 
*  μ: 7-methoxycoumarinylalanine;  AS: thioalanine;  LS: thioleucine;  KS: thiolysine; 
RS: thioarginine; FS: thiophenylalanine   
 
Table 3–5.  HPLC Gradients for Peptide Purification.   
 
No. Time (min) %B  No. Time (min) %B 
1 00:00 002  2 00:00 002 
06:00 002  06:00 002 
08:00 015  08:00 020 
37:00 040  28:00 040 
40:00 100  31:00 100 
45:00 100  36:00 100 
50:00 002  41:00 002 
3 00:00 2  4 00:00 002 
06:00 2  06:00 002 
09:00 20  08:00 027 
24:00 40  24:00 035 
28:00 100  26:00 100 
33:00 100  31:00 100 
48:00 2  36:00 002 
*  Solvent A: 0.1 % TFA in water;  Solvent B: 0.1 % TFA in acetonitrile 
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Table 3–6.  Calculated and Observed Masses of Peptides.   
 
Peptide 
[M+H]+ [M+Na]+ [M+K]+ 
Calculated Observed Calculated Observed Calculated Observed 
μLLKAAAμ 1076.53 1075.81 1098.51 1097.79 1114.49 1113.77 
μLSLKAAAμ 1092.51 1092.44 1114.49 1114.42 1130.46 1130.39 
μLLSKAAAμ 1092.51 1092.42 1114.49 1114.40 1130.46 1130.37 
μLLKSAAAμ 1092.51 1092.87 1114.49 1114.85 1130.46 1130.84 
μLLKASAAμ 1092.51 1092.43 1114.49 1114.41 1130.46 1130.38 
μLLKAASAμ 1092.51 1092.38 1114.49 1114.36 1130.46 1130.43 
μLLKAAASμ 1092.51 1092.52 1114.49 1114.51 1130.46 1130.47 
μLLRAAAμ 1104.54 1104.11 1126.52 1126.11 1142.49 1142.08 
μLLRSAAAμ 1120.51 1120.54 1142.50 1142.53 1158.47 1158.50 
μKAAFAAAμ 1139.50 1139.77 1161.49 1161.80 1177.46 1177.79 
μKSAAFAAAμ 1155.48 1155.54 1177.46 1177.57 1193.44 1193.55 
μKASAFAAAμ 1155.48 1155.68 1177.46 1177.68 1193.44 1193.67 
μKAASFAAAμ 1155.48 1155.12 1177.46 1177.12 1193.44 1193.11 
μKAAFSAAAμ 1155.48 1155.80 1177.46 1177.88 1193.44 1193.93 
μKAAFAASAμ 1155.48 1155.71 1177.46 1177.74 1193.44 1193.73 
*  μ: 7-methoxycoumarinylalanine;  AS: thioalanine;  LS: thioleucine;  KS: thiolysine; RS: thioarginine; 
FS: thiophenylalanine 
 
Steady State Protease Assays  In a typical trial, peptide was incubated in the 
corresponding buffer in the presence or absence of the described concentration of protease 
in a 96 well plate (Table 3–7).  The fluorescence was monitored as a function of time at 
390 nm with an excitation wavelength of 325 nm on the Tecan plate reader.  Three 
independent trials were performed for each assay to ensure reproducibility.  The average 
of the three trials was calculated, and fitted to either an exponential equation (3.1) or a 
hyperbola equation (3.2) to calculate the half-life. 
𝑦 =  𝑦𝑚𝑎𝑥(1 −  𝑒
−𝑘𝑡)                                                    (3.1) 
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𝑦 =  
𝐵𝑚𝑎𝑥𝑥
𝐾 + 𝑥
                                                             (3.2) 
Table 3–7.  Reaction Conditions for Different Proteases.   
 
Protease c(Peptide) (μM) Buffer Temperature 
0.2 mg/mL 
Chymotrypsin 
5.0 μM 100 mM Tris-HCl, pH 7.8 25 °C 
2.5 μg/mL 
Papain 
7.8 μM 
2.0 mM EDTA, 5.00 mM L-
cysteine, 300 mM NaCl, pH 6.2 
27 °C 
25 μg/mL 
Trypsin 
7.8 μM 67 mM sodium phosphate, pH 7.6 25 °C 
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Figure 3–6.  Proteolysis of Trypsin Monitored by Fluorescence.   
 
7.8 µM of peptide was incubated in the presence or absence of 25 µg/mL of trypsin in 67 mM 
sodium phosphate buffer (pH 7.6) at 25 °C.  Three independent trials for each protease are shown 
as open circles, thin lines, and thick lines.  Red trace: thiopeptide in the presence of protease; 
Orange race: thiopeptide in the absence of protease; Green trace: oxopeptide in the presence of 
protease; Blue trace: oxopeptide in the absence of protease. 
  
122 
 
 
 
 
Figure 3–7.  Proteolysis of Trypsin on Substrates with Thioamide at the Scissile Bond.   
 
7.8 µM of peptide was incubated in the presence or absence of 25 µg/mL of trypsin in 67 mM 
sodium phosphate buffer (pH 7.6) at 25 °C.  Three independent trials for each protease are shown 
as open circles, thin lines, and thick lines.  Red trace: thiopeptide in the presence of protease; 
Orange race: thiopeptide in the absence of protease; Green trace: oxopeptide in the presence of 
protease; Blue trace: oxopeptide in the absence of protease.  
 
 
Figure 3–8.  Proteolysis of Papain On µLLRAAAµ and µLLRSAAAµ.   
 
7.8 µM of µLLRAAAµ or µLLRSAAAµ was incubated in the presence or absence of 2.5 µg/mL of 
papain in 2.0 mM EDTA, 5.00 mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27 °C.  Three 
independent trials for each protease are shown as open circles, thin lines, and thick lines.  Red 
trace: thiopeptide in the presence of protease; Orange race: thiopeptide in the absence of protease; 
Green trace: oxopeptide in the presence of protease; Blue trace: oxopeptide in the absence of 
protease. 
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Figure 3–9.  Proteolysis of Papain Monitored by Fluorescence.   
 
7.8 µM of peptide was incubated in the presence or absence of 2.5 µg/mL of papain in 2.0 mM 
EDTA, 5.00 mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27 °C.  Three independent trials for 
each protease are shown as open circles, thin lines, and thick lines.  Red trace: thiopeptide in the 
presence of protease; Orange race: thiopeptide in the absence of protease; Green trace: 
oxopeptide in the presence of protease; Blue trace: oxopeptide in the absence of protease. 
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Figure 3–10.  Proteolysis of Chymotrypsin Monitored by Fluorescence.   
 
5.0 µM of peptide was incubated in the presence or absence of 0.2mg/mL of chymotrypsin in 100 
mM Tris-HCl buffer (pH 7.8) at 25 °C.  Three independent trials for each protease are shown as 
open circles, thin lines, and thick lines.  Red trace: thiopeptide in the presence of protease; Orange 
race: thiopeptide in the absence of protease; Green trace: oxopeptide in the presence of protease; 
Blue trace: oxopeptide in the absence of protease. 
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Inhibition Assay  Various concentrations of trypsin substrate N-benzoyl-L-arginine-
4-nitroanilide (Bz-Arg-pNA) (10 μM, 50 μM, 100 μM, 500 μM, 1 mM, 1.5 mM, 2.0 mM, 
3.0 mM and 4.0 mM) was reacted with 40 μg/mL trypsin in 67 mM sodium phosphate 
buffer, pH 7.6, at 25 °C in a 96-well plate.  For thioamide inhibition, 1 μM or 10 μM of 
thiopeptide was incubated with 40 μg/mL trypsin for 15 min at 25 °C to allow for full 
interactions before adding the Bz-Arg-pNA substrates.  The reaction was monitored by 
UV-Vis absorbance at 410 nm by the plate reader.  Three trials were performed to ensure 
reproducibility.  From the extinction coefficient of p-nitroaniline as 8800 M-1∙cm-1, the 
absorbance was converted into the product p-nitroaniline concentration.  The reaction rate 
is calculated by extracting the slope of a linear fitting of the first 2 minutes of product 
concentration to time.  The average of reaction rates from three trials were calculated and 
fitted into a Michaelis-Menten equation to obtain kcat and KM values. 
 
Figure 3–11.  Trypsin Activity Monitored by Colorimetric Substrate Bz-Arg-pNA.   
 
40 µg/mL Trypsin was incubated with 10 µM µLLKSAAAµ, then mixed with various concentrations 
of Bz-Arg-pNA.  Data are colored according to substrate concentration: maroon 10 µM; red 50 µM; 
orange 100 µM; yellow 500 µM; lime 1 mM; emerald 1.5 mM; cyan 2 mM; blue 2.5 mM; purple 3 
mM; pink 4 mM. 
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Figure 3–12.  Michaelis-Menten Fit of Trypsin Inhibition by Thiopeptides.   
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Table 3–8.  Kinetic Parameters Obtained for Trypsin Inhibition.   
 
Thiopeptide kcat (sec-1) KM (mM) kcat / KM (M-1∙sec-1) 
No Thiopeptide 0.379 ± 0.030 0.846 ± 0.195 0.447 ± 0.109 
01 µM μLLKSAAAμ 0.529 ± 0.037 1.234 ± 0.231 0.428 ± 0.085 
10 µM μLLKSAAAμ 0.476 ± 0.007 1.018 ± 0.043 0.468 ± 0.021 
01 µM μLLRSAAAμ 0.422 ± 0.028 0.917 ± 0.187 0.461 ± 0.099 
10 µM μLLRSAAAμ 0.381 ± 0.021 1.183 ± 0.180 0.322 ± 0.052 
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Chapter 4 .  Thioamides Suppress Dipeptidyl Peptidase 4 Cleavage of Therapeutic 
Peptide Hormones While Maintaining In Vivo Activity 
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4.1  Introduction 
Diabetes mellitus, commonly referred as diabetes, remains the 7th leading cause of 
death in US in 2010, and affects 9.3% of entire US population251.  In addition, because of 
the increased risk of many serious complications, including cardiovascular diseases, the 
risk of death for diabetic adults is 50 % higher than for adults without diabetes.  Although 
there is no cure, diabetes can still be treated and controlled by healthy lifestyle and 
therapeutic intervention, including a number of peptide therapeutics developed from 
peptide hormones which can regulate blood glucose level.  Aside from insulin, the most 
well characterized and highly developed peptide hormone is glucagon like peptide 1 (GLP-
1)252-253. 
GLP-17-36 amide or GLP-17-37 (both forms exist naturally and exhibit identical 
bioactivity), referred to simply as GLP-1, has a variety of anti-diabetic roles including 
stimulating insulin, suppressing glucagon secretion, inhibiting gastric emptying, and 
reducing appetite and food intake254.  It is of great interest as a diabetes treatment because 
GLP-1 has two advantages over direct insulin injection or other direct stimulators of insulin 
secretion currently on the market255.  The first advantage is that GLP-1 only stimulates 
insulin secretion in the presence of glucose, so that it augments the natural physiological 
mechanism for insulin secretion and has lower hypoglycemia risks.  The second advantage 
is that GLP-1 will not cause increased stress of pancreatic β-cells which may lead to cell 
death, as compared to insulin direct stimulators.  However, treatment by direct GLP-1 
injection is not feasible because it is inactivated by dipeptidyl peptidase 4 (DPP-4) 
proteolysis with a half-life of less than 2 min94.  In fact, DPP-4 is the principal determinant 
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of the circulating half-life for GLP-1256.  Current therapeutic approaches for enhancing the 
insulin-secreting activity mediated by GLP-1 include both degradation-resistant GLP-1 
receptor (GLP-1R) agonists and DPP-4 inhibitors.  Several GLP-1 mimetics, including 
exenatide (Byetta®, Bydureon®; AstraZeneca)257-258, liraglutide (Victoza®; Novo 
Nordisk)259-260, lixisenatide (Adlyxin® in US, Lyxumia® in Europe; Sanofi)261, albiglutide 
(Tanzeum®; GlaxoSmithKline)137-138, and dulaglutide (Trulicity®; Eli Lilly)262 have been 
introduced to the market with great success101.  In addition, as of today, more than 30 GLP-
1R agonists are under development in clinical or preclinical trials263.  Some selected 
examples are shown in Table 4–1101.  Despite the appealing feature of small molecule 
DPP-4 inhibitors like sitagliptin (Januvia®; Merck) as orally available therapeutics, 
injectable GLP-1 mimetics remain in great need because they can produce some desirable 
effects, such as appetite suppression and weight loss, that DPP-4 inhibitors lack264-265, as 
well as because there are concerns about increased risk of cancer from DPP-4 inhibition95. 
Table 4–1.  Selected GLP-1R Agonists in Pipeline.   
 
Company Peptide Name Development Stage Dosing 
Eli Lilly Cpd86 Preclinical SC, once daily 
Zealand Pharma ZPGG-72/ZP3022 Preclinical SC, once daily 
Zealand Pharma ZP2929 Phase II SC, once daily 
Hanmi Pharmaceuticals HM12525A Phase I SC, once weekly 
Diartis Pharmaceuticals VSR-859 Phase I SC, once monthly 
Novo Nordisk NN9828 Phase II SC, once monthly 
TransTech Pharma TTP273/TTP054 Phase II Oral 
Hanmi Pharmaceuticals Efpeglenatide Phase II SC, once weekly 
PhaseBio Pharmaceuticals PB1023 Phase II SC, once weekly 
Novo Nordisk NN9924 Phase III Oral, long acting 
Novo Nordisk Semaglutide Filed SC, once weekly 
Intarcia ITCA650 Filed SC, once yearly 
*  SC: subcutaneous.  Adapted and updated from Fosgerau and Hoffmann101 
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A variety of stabilization strategies have been applied to GLP-1 to block DPP-4 from 
accessing the cleavable bond (Figure 4–1).  Exenatide achieves enhanced degradation 
resistance through only natural amino acid substitutions in the peptide sequence264.  
Lixisenatide derives from exenatide, omitting Pro38 but adding six Lys residues at the C-
terminus261, 266.  Liraglutide includes a fatty acid modified sidechain, which binds to 
albumin to reduce kidney clearance267.  Albiglutide is a dimer of mutated GLP-1, which 
has an Ala to Gly mutation at the scissile bond, fused to human albumin protein to achieve 
the same effect137-138.  Dulaglutide is also a fusion of GLP-1 and an Fc fragment of human 
antibody IgG4, which protects the scissile bond and slows renal clearance262.  Unnatural 
amino acid modification, specifically aminoisobutyric acid (Aib or α), is also explored to 
enhance GLP-1 resistance to DPP-4 and stabilize GLP-1 conformations.  Semaglutide, for 
which Novo Nordisk has filed for regulatory approval, combines fatty acid modification 
with Aib substitution at the scissile bond to create a long acting GLP-1 analog268-269.  The 
Gellman group replaced Ala8 and Val16 with Aib, and also made extensive β-amino acid 
substitutions in GLP-1104.  The stapling strategy (discussed in Chapter 1) was also explored 
by several groups to stabilize the helical conformation of GLP-1 to enhance its DPP-4 
resistance and GLP-1R activation ability119-120.  While there are many other strategies 
employed to stabilize GLP-1, these examples here represent the most successful ones 
explored currently. 
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Figure 4–1.  Selective Examples of Stabilized GLP-1 Based Diabetes Therapeutics.   
 
Red slash indicates DPP-4 cleavage site of GLP-1.  Fc: Fc fragment of human antibody IgG4.   
 
Although these stabilized GLP-1 analogs have been successful, we should not ignore 
the tremendous efforts invested.  It is difficult to predict the impact of the modifications at 
a certain position, so extensive structure activity relationship studies are required to 
determine the best locations for these stabilization modifications.  In addition, some of the 
modifications are not easily installed, so that they require additional studies into suitable 
installation strategies or are restricted to only a few positions.  Finally, although ideal 
locations and installation methods for these stabilization strategies have been determined 
for GLP-1, they may not be translatable to other peptides of therapeutic interests.   
Given the limitations of existing stabilization strategies, we propose to use thioamide 
substitution at or near the scissile bond as a universally applicable, simple method for 
stabilizing peptides against degradation (Figure 4–2).   
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Figure 4–2.  Thioamides Prevent Peptide Inactivation by Proteolysis.   
 
Native GLP-1 is inactivated by DPP-4 cleavage at the scissile bond, indicated by a red slash. 
 
Peptide substrates containing a thioamide substitution at the scissile bond have been 
previously investigated as potential inhibitors of a variety of proteases.  In most cases, 
thioamide analogs are found to be weak competitive inhibitors, with similar affinity but 
significantly smaller turnover rate as compared to oxoamide substrates.  It is a slightly 
different case with DPP-4.  One study showed that a thioamide at the P2 position of DPP-
4 substrate Ala-Pro-pNA (pNA is p-nitroaniline), generated a 650-fold decrease in kcat/KM 
value compared with the oxoamide compound (Table 4–2)270.  However, this stability 
derived from a combination of a decreased kcat and an increased KM, which was the main 
factor.  Another study with a thioamide substitution at the P1 position of various DPP-4 
inhibitors also revealed increased Ki, ranging from 4 to 9 folds, relative to oxoamide 
inhibitors.  This kinetic feature of thioamide-containing peptides negates their use as good 
protease inhibitors, but raises the idea of generating proteolytically resistant peptides.  To 
our knowledge, there have been very few investigations in developing thioamide 
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substitution in peptides as a stabilization strategy, and only one study comparing the half-
lives of thioamide and oxoamide peptides in animals212. 
Table 4–2.  Kinetic Constants for Thioamide and Oxoamide DPP-4 Substrates.   
 
Substrate kcat (sec-1) KM (mM) kcat / KM (M-1∙sec-1) 
Ala-Pro-pNA 54.6 ± 0.02 0.011 ± 0.0004 (4.7 ± 0.18) × 106 
AlaS-Pro-pNA 02.8 ± 0.14 0.390 ± 0.0320 (7.2 ± 0.49) × 103 
*  pNA: p-nitroaniline; AlaS: thioalanine.  Adapted from Schutkowski et al.270 
 
Thioamide incorporation into peptides and proteins have been further developed and 
improved in our lab recently, allowing access to thioamide-containing peptides of greater 
than 30 amino acids, as well as to thioamide-containing proteins via NCL181, 197.  In theory, 
thioamides can be introduced at any given chose position using standard solid phase 
peptide synthesis.  Moreover, thioamide substitution is easily coupled with other strategies 
to achieve synergistic results, such as the attachment of fatty acids to prevent renal 
clearance, or the emerging trend in developing chimeric agonists271-272. 
Finally, thioamide substitution at or near the scissile bond is likely to be a general 
strategy to stabilize peptides against proteolysis, and we wished to demonstrate this with 
DPP-4 substrates other than GLP-1 as well.  In fact, over 25 peptides with a variety of 
signaling functions have been identified as DPP-4 substrates, including glucagon, gastric 
inhibitory polypeptide (GIP)256, 273, vasoactive intestinal peptide274, pancreatic 
polypeptide274, peptide YY275, neuropeptide Y (NPY)275, oxyntomodulin276-279, brain 
natriuretic peptide280, enterostatin281, growth-hormone releasing hormone282, substance P 
(SP)283-285, and several cytokines286-287.  All these DPP-4 substrates have in vivo half-lives 
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of less than an hour, less than 15 min in most cases, and many have potential therapeutic 
interest.  Like GLP-1, GIP acts as a glucose-lowering agent and has been studied 
extensively as a diabetes treatment288-290.  There is also substantial interest in developing 
GLP-1/GIP fusion peptides which target receptors of both peptides272.  Unlike GLP-1, there 
are no current stabilized GIP available for therapeutic purposes. 
Here, we introduce thioamide modification into two peptides of therapeutic interest, 
GLP-1 and GIP, to demonstrate the potential of thioamide substitution as peptide 
stabilization strategy in a general and straightforward manner. 
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4.2  Results and Discussion 
We began our investigation by assessing the in vitro stability of all the GLP-1 peptides, 
that is GLP-1, GLP-1-F7, and thioamide analogs GLP-1-F
S
7, GLP-1-A
S
8, GLP-1-F7A
S
8, 
and GLP-1-ES9.  These peptides were synthesized using established solid phase peptide 
synthesis protocol with a combination of automated peptide synthesizer and manual 
synthesis, purified by high performance liquid chromatography (HPLC), and characterized 
by matrix-assisted laser desorption ionization – time of flight mass spectrometry (MALDI-
TOF MS).  No difference was observed in secondary structure between native GLP-1 and 
the GLP-1 thiopeptides (Figure 4–7).  Purified peptides were incubated in buffer alone or 
with 2.5 ng/µL DPP-4 at 37 °C for different time periods. The reaction was then quenched 
and analyzed by analytical HPLC to determine the amount of intact peptide.  The in vitro 
half-life of GLP-1-AS8 (P1 position) in the presence of DPP-4 was found to be 3.4 h while 
the half-life of native GLP-1 to be only 1.8 min (Figure 4–3, Figure 4–17, Table 4–7).  In 
fact, further investigation showed that the majority of the GLP-1-AS8 degradation we 
observed was not due to DPP-4 proteolysis, but arose from an intramolecular reaction as a 
result of the presence of the N-terminal His residue in GLP-1-AS8 (Figure 4–11, Figure 
4–13).  On the other hand, GLP-1-ES9 (P1' position) was stable in buffer, but had a half-
life of < 5 min with DPP-4 incubation (Figure 4–9).  Unfortunately, we were unable to 
generate enough GLP-1-HS7 for such testing. 
Since GLP-1 and GLP-1-F7 have been reported to have similar bioactivity
291, we chose 
GLP-1-F7 as a model system to study the placement of thioamide at the P1 (GLP-1-F7A
S
8) 
and P2 (GLP-1-FS7) positions.  GLP-1-F7 lacks the N-terminal imidazole moiety, which 
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we believed to act as a catalyst in auto-degradation of GLP-1-AS8.  Indeed, both GLP-1-
F7A
S
8 and GLP-1-F
S
7 were stable in buffer (Figure 4–10).  In the presence of DPP-4, the 
half-life of GLP-1-F7 is 2.6 min, while the half-life of GLP-1-F7A
S
8 and GLP-1-F
S
7 are 
25.7 h and 12.1 h respectively (Figure 4–3).  Collectively, thioamide placement near the 
scissile bond of GLP-1 can confer a 600-fold increase in peptide stability against DPP-4 
proteolysis. 
 
Figure 4–3.  Thioamide Substitution Stabilizes GLP-1 Analogs Without Disrupting Activity.   
 
A)  Sequences of GLP-1 and GLP-1-F7.  B)  In vitro DPP-4 proteolysis of GLP-1 and its analogs, 
GLP-1-F7, GLP-1-FS7, and GLP-1-F7AS8.  Thioamide analogs have half-lives of 200- to 1000-fold 
longer than their respective oxopeptides when incubated with 2.5 ng/mL DPP-4.  C)  GLP-1R 
activation dose response curves for GLP-1, GLP-1-F7, GLP-1-FS7, and GLP-1-F7AS8.  GLP-1, GLP-
1-F7, and GLP-1-FS7 had almost identical EC50, while GLP-1-F7AS8 was less potent. 
 
To investigate whether thiopeptides act as inhibitors of DPP-4, Pro-Ala-pNA, a 
commercial chromogenic substrate of DPP-4 was used to monitor DPP-4 kinetics.  Various 
concentrations of GLP-1 thiopeptide analogs were mixed with 2.5 ng/µL DPP-4 and 
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incubated at room temperature for 15 min to allow for full binding.  Upon addition of 100 
µM Pro-Ala-pNA, the spectral change from the cleaved pNA was monitored as a function 
of time.  GLP-1-AS8 (P1 position) and GLP-1-F
S
7 (P2 position) were found not to inhibit 
DPP-4 activity at concentrations up to 70 µM (Figure 4–16), consistent with the idea that 
their stability against DPP-4 proteolysis originated from an effect on binding. 
Of course, to be valuable, GLP-1 thioamide analogs must retain potency similar to 
native GLP-1 in GLP-1R activation.  Engineered CHO-K1 cell lines overexpressing GLP-
1R were purchased from DiscoveRx to detect changes in intracellular cAMP levels in 
response to GLP-1R stimulation by GLP-1 derivatives.  EC50s of each GLP-1 analog were 
determined (Table 4–7).  GLP-1-FS7 was found to be essentially equipotent with native 
GLP-1, with an EC50 of 0.24 nM (Figure 4–3).  GLP-1-AS8 is 12-fold less potent compared 
to GLP-1, and GLP-1-F7A
S
8 is 16-fold less potent compared to GLP-1-F7 (Figure 4–3), 
showing that a thioamide at the 2nd position of GLP-1 may slightly interfere with its 
interaction with GLP-1R. 
To confirm the in vivo bioactivity of this peptide, and as a preliminary step towards 
evaluating its potential pharmacotherapeutic relevance, the effects of GLP-1-FS7 on 
glycemic control were compared to the effects of native GLP-1 in adult male Sprague-
Dawley rats.  Rats were utilized as the animal model for two reasons: 1) their slower 
metabolism relative to mice provides a more translatable test of pharmacokinetics, and 2) 
unlike mice, rats recapitulate many of the behavioral and physiological profiles of GLP-1 
signaling found in humans292-295.  The glycemic profile of GLP-1-FS7 was compared to that 
of native GLP-1 in an oral glucose tolerance test (OGTT).  Rats were fasted overnight, and 
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OGTT was initiated shortly after the onset of the dark phase.  After measuring fasting blood 
glucose levels using a standard glucometer (time = -20 min), rats (n=16) received 
intraperitoneal (IP) injection of vehicle (1 mL/kg sterile 0.9 % NaCl, pH 7.0 – 7.4), GLP-
1 (0.5 mg/kg), or GLP-1-FS7 (0.5 mg/kg).  Twenty minutes later (time = 0 min), blood 
glucose was measured again, and each rat received an oral glucose load (2 g/kg) by gavage.  
Blood glucose was measured again at 20, 40, 60, and 120 min post-glucose load to evaluate 
the effects of each compound on glycemic control.  As expected, native GLP-1 produced 
a significant reduction in blood glucose levels at 20 min post-glucose load (Figure 4–4).  
Intriguingly, GLP-1-FS7 suppressed blood glucose at 20 and 40 min post-glucose load, and 
was significantly more effective at lowering blood glucose levels at these times than native 
GLP-1.  These data suggest that the glycemic benefits of GLP-1-FS7 are more potent and 
more durable than that of native GLP-1 when administered at doses near the GLP-1 EC50 
in rats (0.5 mg/kg).  This suggests that the glycemic benefits of GLP-1 are retained and 
even enhanced with thioamide modification, and furthermore, demonstrates that the 
equipotency seen in cellular assays (Figure 4–3) is maintained in vivo. 
We also performed a limited dose-response experiment in the same rats (n=16) to 
evaluate the effects of different doses of GLP-1-FS7 on glycemic control.  The methods 
were the same as the first OGTT, except GLP-1-FS7 was administered at doses ranging 
from 0.25 – 1.0 mg/kg (vehicle = 1 mL/kg sterile 0.9 % NaCl, pH 7.0 – 7.4).  The results 
showed that all doses of GLP-1-FS7 tested significantly suppressed blood glucose levels at 
20 min after glucose gavage compared to vehicle, while the two higher doses (0.5 and 1.0 
mg/kg) continued to reduce blood glucose at 40 min post-gavage (Figure 4–4).  The two 
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higher doses of GLP-1-FS7 tested also suppressed blood glucose levels significantly more 
than did the 0.25 mg/kg dose, indicating a dose-responsive effect of the compound on 
glycemic control. 
 
Figure 4–4.  Thioamide GLP-1 Analog Suppresses Blood Glucose in Rats.   
 
A)  OGTTs measure the activity of GLP-1 and GLP-1-FS7 at does near the EC50 of GLP-1 (0.5 
mg/kg).  Enhanced suppression of blood glucose was observed with GLP-1-FS7 compared to GLP-
1.  B)  Does response data of GLP-1-FS7 suppressing blood glucose. 
 
To demonstrate that this strategy can be extended to other DPP-4 substrates, a 
thioamide was placed at the P2 or P1 position of GIP.  No observation of auto-degradation 
was observed for either GIP derivative, further confirming that the auto-degradation of 
GLP-1-AS8 is unique to itself with an N-terminal His followed by a thioamide. 
For GIP, we found that modification at the P2 (GIP-YS1) or the P1 (GIP-A
S
2) position 
increased peptide half-life in the presence of 2.5 ng/mL DPP-4 to 68 h and 60 h, 
respectively. (Figure 4–5)  The approximately 800-fold increase in half-life (GIP t1/2 = 5 
min) for these GIP thiopeptides is significantly greater than for GLP-1-F7 thiopeptides.  
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Like GLP-1-FS7 (P2) and GLP-1-F7A
S
8 (P1), GIP-Y
S
1 is not a competitive inhibitor of 
DPP-4 (Figure 4–16).  To measure the potency of GIP-YS1 and GIP-AS2, we again turned 
to cAMP reporter cell lines.  The results of dose-response experiments were similar to those 
for GLP-1 (Figure 4–5).  P1-substituted GIP-AS2 was 40-fold less potent than GIP, but P2-
substituted GIP-YS1 was nearly equipotent (EC50s: GIP, 161 pM; GIP-Y
S
1, 430 pM; GIP-
AS2, 6522 pM).  This is perhaps not surprising, since the mode of GIP binding to GIPR is 
believed to be similar to GLP-1 binding to GLP-1R296.  However, since this region is not 
resolved in the structural models of glucagon-like receptors (based on the structure of the 
extracellular domain of GLP-1R and the full-length structure of the related glucagon 
receptor), the precise reasons for P1 being disruptive and P2 being tolerated are not clear297-
299.  
 
Figure 4–5.  Thioamide Substitution Stabilizes GIP Without Disrupting Activity.   
 
A)  Sequence of GIP.  B)  In vitro DPP-4 proteolysis of GIP and its thioamide analogs, GIP-YS1, 
and GIP-AS2.  Thioamide analogs showed nearly 800-fold increase in their half-lives compared to 
GIP when incubated with 2.5 ng/µL DPP-4.  C)  GIPR activation dose response curves for GIP, 
GIP-YS1, and GIP-AS2.  GIP-YS1 was equally potent as GIP, while GIP-AS2 showed a higher EC50. 
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To explain how a thioamide at the P1 or P2 position of GLP-1 and GIP disrupt DPP-
4 activity, we turned into the crystal structure of DPP-4 in complex of a partial sequence 
of neuropeptide Y (Figure 4–6).  It was shown that both the carbonyl groups at the P1 and 
P2 positions are involved in hydrogen bonding with DPP-4.  With a thioamide substitution, 
whose C=S bond is slightly longer and a worse hydrogen bond acceptor compared to the 
native C=O bond, it is possible these hydrogen bonding is disrupted, leading to poor 
recognition of thiopeptides by DPP-4.  In addition, given the important role of oxyanion 
hole in serine proteases, it is also possible that the tetrahedral intermediate of thiopeptides 
cannot be sufficiently stabilized, leading to slow turnover. 
 
Figure 4–6.  Crystal Structure of DPP-4 in Complex with Part of Neuropeptide Y.   
 
A)  Interactions between DPP-4 and part of neuropeptide Y at the active site.  DPP-4 is shown in 
green; neuropeptide Y is shown in grey; the carbonyl oxygens at the P1 and P2 positions are shown 
in orange and yellow spheres; interactions are shown in dotted lines.  B)  Key interactions involving 
the carbonyl group at the P1 and P2 positions.  Distance were measured between those 
interactions.  Adapted from Aertgeerts et al. (PDB ID 1R9N)300. 
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Although the glycemic benefits of GLP-1 are retained and even enhanced with 
thioamide substitution at short time frames, there is no significant difference in the 
glycemic effects between GLP-1-FS7 and GLP-1 or the vehicle over timescales longer that 
40 min in rats.  This is presumably due to kidney clearance effects, which could be 
addressed with fatty acid modification, as in semaglutide. 
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4.3  Conclusion 
We have synthesized thioamide-substituted versions of two clinically-relevant 
peptides and shown that the single atom, oxygen-to-sulfur substitution of the thioamide can 
work as a simple strategy to stabilize peptides toward proteolysis while preserving 
bioactivity.  Thioamide substitution at positions near the scissile bond in GLP-1 and GIP 
renders these peptides 400 to 800-fold more stable toward DPP-4 cleavage than the 
corresponding oxopeptides.  GLP-1 and GIP thiopeptide analogs substituted at the amino 
acid preceding the scissile bond (P2 position) are nearly equipotent with the parent peptide 
in cell-based assays.  Finally, proof-of-concept tests show that a thioamide GLP-1 analog 
is active in rats, with an in vivo potency surpassing that of GLP-1.  Taken together, these 
experiments demonstrate that judicious placement of thioamide bonds can be a simple, and 
potentially general, strategy for stabilizing peptides in therapeutic and diagnostic 
applications.  Thioamide substitution should be particularly useful in drug discovery, where 
its straightforward implementation can allow one to quickly take a newly identified 
signaling peptide and create a proteolytically-stable version for in vivo study. 
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4.4  Future Directions 
With the success seen with GLP-1 and GIP, we would like to test this strategy with 
more DPP-4 substrates, such as NPY and SP.  NPY targets Y receptors (YRs), which are 
over-expressed in a variety of human cancers, such as breast carcinomas and 
neuroblastomas, making YR ligands attractive targets for cancer diagnosis and therapy301-
303.  SP is associated with multiple physiological processes: hematopoiesis, wound healing, 
microvasculature permeability, neurogenic inflammation, leukocyte trafficking, and cell 
survival283.  As NPY and SP have a Pro at the P1 position, it is interesting to see whether 
substrate side chains will have an impact on thioamide stabilization strategy. 
We would also like to expand our studies beyond DPP-4 substrates.  One interesting 
subject is anti-diabetic amylin, which features a site of internal proteolysis by insulin 
degrading enzyme (IDE, a Zn metalloprotease).  Amylin (also known as islet amyloid 
pancreatic peptide, IAPP) is a hormone that also possesses favorable effects toward 
diabetes and obesity.  Like GLP-1, amylin is metabolized by renal clearance and 
proteolysis, giving it a half-life of less than one hour304-305.  Native human amylin is also 
prone to aggregation, making it unsuitable as an injectable306.  There is a possibility that 
the same thioamide location will both block proteolysis and aggregation, simultaneously 
solving two common peptide biologic problems. 
To better understand the mechanism of thioamide resistance to DPP-4 proteolysis, 
more rigorous mechanistic studies are in need.  It is practical, but also laborious to obtain 
the kinetic parameters of DPP-4 proteolysis of GLP-1 and thioamide-modified GLP-1 
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analogs by HPLC analysis.  Considering the success of thioamide-based fluorescent probes 
to detect protease activity, it may be possible to monitor DPP-4 proteolysis by a thioamide-
fluorophore doubly labelled GLP-1.  In addition, a crystal structure of thiopeptide bound 
DPP-4 would shed light on the interactions between DPP-4 and the thioamide. 
To explore the potential of the utility of thiopeptides as therapeutics, a variety of 
preclinical studies, such as pharmacodynamics, pharmacokinetics and toxicology studies, 
are needed to evaluate thioamide-modified GLP-1 analogs.  Moreover, the thioamide 
strategy can be combined with other peptide stabilization methods, such as fatty acid 
attachment or albumin fusion to create long-lasting GLP-1 analogs as potential treatments 
for diabetes. 
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4.5  Materials and Methods 
General Information  Boc-L-thionophenylalanine-1-(6-nitro)benzotriazolide and H-
Ala-Pro-pNA (AP-pNA) was purchased from Bachem (Torrance, CA, USA).  All Fmoc 
protected amino acids and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) were purchased from Novabiochem (currently EMD 
Millipore; Billerica, MA, USA).  Piperidine was purchased from American Bioanalytical 
(Natick, MA, USA).  Sigmacote®, N,N-diisopropylethylamine (DIPEA), and human 
Dipeptidyl Peptidase 4 (DPP-4) (recombinant, expressed in Sf9 cells) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).  All other reagents were purchased from Fisher 
Scientific (Pittsburgh, PA, USA) unless specified otherwise.  Milli-Q filtered (18 MΩ) 
water was used for all solutions (EMD Millipore).  Luminescence and time-course UV-Vis 
absorbance were obtained with a Tecan Infinite® M1000 PRO plate reader (San Jose, CA, 
USA).  Peptides were purified with a Varian ProStar High-Performance Liquid 
Chromatography (HPLC) with a diode array detector (currently Agilent Technologies), and 
analyzed with an Agilent 1100 Series HPLC system.  Peptide mass spectrometry were 
collected with a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer (Billerica, MA, 
USA). 
Peptide Synthesis and Purification  All peptides were synthesized by a combination 
of automated and manual synthesis.  GLP-110-37 and GIP3-42 were either ordered from 
GenScript (Piscataway, NJ, USA) and delivered as protected peptides on dry resins, or 
synthesized on a CEM Liberty 1 automated microwave peptide synthesizer (Matthews, NC, 
USA) according to the company recommended protocol.  The remaining residues were 
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synthesized manually using our established protocols.  Specifically, for all GLP-1 and GIP 
related peptides, following procedures were used.  Prior to use, the glass peptide reaction 
vessel (RV) was coated with Sigmacote® (Sigma-Aldrich).  Each reaction was repeated 
twice to ensure good yield.  Between each reaction, the resin was washed extensively with 
dimethylforamide (DMF).  For deprotection, 20 % piperidine in DMF was added to the RV 
and allow for successive 5 min and 15 min incubation with resins under magnetic stirring.  
For normal amino acids coupling, 5 equiv. amino acid and 5 equiv. HBTU were dissolved 
in DMF, and then added to the RV, with 10 equiv. DIPEA.  The reaction was allowed to 
proceed for 30 min with stirring.  Thioamides were incorporated through pre-activated 
benzotriazole precursors.  2 equiv. thioamide precursor in dry dichloromethane (DCM) was 
added to the RV with 2 equiv. DIPEA, and stirred for 45 min.  For cleavage, the resin was 
incubated with a fresh cleavage cocktail (trifluoroacetic acid: water: triisopropylsilane = 
95 : 2.5 : 2.5, v/v) on a rotisserie for 30 min then 45 min.  After each cleavage, the cocktail 
solution containing peptides was expelled from the RV and mixed with cold ether on dry 
ice for 10 min.  The mixture was centrifuged at 3000 rpm for 5 min, and the precipitates 
were collected and dissolved in CH3CN/H2O (1:1 v/v) for purification by HPLC.  Peptides 
were purified on a SunFire C18 Prep column (Waters; Milford, MA, USA) using solvent 
gradients described in Table 4–3. 
Retention times and MALDI-TOF MS characterization of each peptide were shown 
in Table 4–4.  Purified peptides were dried on a lyophilizer (Labconco; Kansas City, MO, 
USA) or in a vacuum centrifuge (Savant/Thermo Scientific; Rockford, IL, USA).  If needed, 
peptides were subjected to multiple rounds of purification until 99% purity was achieved. 
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Table 4–3.  HPLC Gradients for Peptide Purification.   
 
Peptide Time (min) %B  Peptide Time (min) %B 
GLP-1-AS8 00:00 002  GLP-1-ES9 00:00 002 
06:00 002  06:00 002 
08:00 025  08:00 020 
27:00 037  37:30 045 
30:00 100  40:00 100 
35:00 100  45:00 100 
40:00 002  50:00 002 
GLP-1-F7 
GLP-1-F7AS8 
00:00 002  GLP-1-FS7 00:00 002 
06:00 002  06:00 002 
08:00 020  08:00 025 
38:00 040  38:00 045 
40:00 100  40:00 100 
45:00 100  45:00 100 
40:00 002  40:00 002 
GIP-YS1 00:00 002  GIP-AS2 00:00 002 
06:00 002  06:00 002 
07:00 015  08:00 020 
37:00 035  37:00 040 
40:00 100  40:00 100 
45:00 100  45:00 100 
40:00 002  50:00 002 
*  Solvent A: 0.1 % TFA in water;  Solvent B: 0.1 % TFA in acetonitrile 
 
Table 4–4.  Retention Time and Masses of Purified Peptides.   
 
Peptide Retention Time (min) Calculated [M+H]+ Observed [M+H]+ 
GLP-1-AS8 27 3313.65 3313.30 
GLP-1-ES9 36 3313.65 3313.67 
GLP-1-F7 35 3307.68 3307.69 
GLP-1-FS7 31 3323.66 3323.05 
GLP-1-F7AS8 36 3323.66 3323.40 
GIP-YS1 31 4999.46 4999.74 
GIP-AS2 25 4999.46 4999.37 
 
  
150 
 
 
 
Peptide Secondary Structure  40 µM of peptide in 10 mM potassium phosphate 
buffer (pH 7.2) containing 30 % trifluoroethanol was prepared in 1 mm quartz cuvettes for 
circular dichroism (CD) measurements of its secondary structure.  Far-UV spectra were 
collected on a CD spectrometer (Aviv Biomedical, Inc.; Lakewood, NJ, USA) at 25 °C.  
Each scan was accumulated from 300 nm to 185 nm with a bandwidth of 1 nm and scanning 
speed of 10 s/nm.  Three scans were repeated to ensure reproducibility, and the average 
was calculated.  Final data were shown after solvent background subtraction. 
 
Figure 4–7.  Retained Secondary Structure in Thioamide Analogs.   
 
A)  CD spectra of GLP-1, GLP-1-F7, GLP-1-AS8, GLP-1-F7AS8, and GLP-1-FS7.  B)  CD spectra of 
GIP, GIP-YS1 and GIP-AS2. 
 
In Vitro Stability Assay  35 µM peptide of interest was incubated in Dulbecco's 
Phosphate-Buffered Saline (DPBS, Corning 21-031-CM) at 37 °C in the absence or 
presence of 2.5 ng/µL DPP-4.  50 µM L-tryptophan was also added into the mixture to 
serve as an internal standard for peptide quantification.  After certain time of incubation, 
the reaction was quenched by an addition of 10% (v/v) 0.1 M HCl.  Samples were kept at 
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−80 °C if not analyzed immediately by HPLC.  a Phenomenex Luna C8(2) analytical 
column (Torrance, CA, USA) was used to analyze all samples using gradients shown in 
Table 4–6.  MALDI-TOF MS was used to check peptide identifies (Table 4–5).  The 
amount of intact peptide was quantified based on peak areas in HPLC chromatograms 
(Figure 4–8).  Specifically, GLP-1 and GIP peptides were monitored at 280 nm, and NPY 
peptides were monitored at 215 nm.  In each chromatogram, the peak area of intact peptide 
was normalized to that of internal standard.  For each time point, 3 runs were conducted 
and the average of the normalized peak areas was calculated.  At time 0, the average 
normalized peak area was assigned as 100 %, and the average normalized peak area of 
intact peptide at different time points comparing to time 0 were calculated as intact peptide 
percentage.  Intact peptide percentage data were fitted to a single-phase exponential 
equation to determine half-life values. 
Table 4–5.  Retention Time and Masses of Peptides from HPLC Analysis.   
 
Peptide Retention Time (min) Calculated [M+H]+ Observed [M+H]+ 
GLP-1 37.3 3297.67 3297.73 
GLP-1-AS8 37.4 3313.65 3313.18 
GLP-1-ES9 37.5 3313.65 3313.11 
GLP-1-F7 39.0 3307.68 3307.44 
GLP-1-FS7 39.3 3323.66 3323.84 
GLP-1-F7AS8 39.5 3323.66 3323.58 
GLP-19-37 38.2 3089.58 3089.16 
GIP 32.0 4983.48 4983.85 
GIP-YS1 32.2 4999.46 4999.79 
GIP-AS2 32.4 4999.46 4999.94 
GIP3-42 31.4 4749.38 4749.58 
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Table 4–6.  HPLC Gradients for Peptide Analysis.   
 
Peptide Time (min) %B  Peptide Time (min) %B 
GLP-1 and  
its analogs 
00:00 002  GIP and  
its analogs 
00:00 002 
05:00 002  05:00 002 
10:00 010  10:00 010 
40:00 040  35:00 035 
45:00 100  40:00 100 
50:00 100  45:00 100 
55:00 002  50:00 002 
*  Solvent A: 0.1 % TFA in water;  Solvent B: 0.1 % TFA in acetonitrile 
 
 
Figure 4–8.  Representative HPLC Chromatogram of In Vitro DPP-4 Proteolysis.   
 
DPP-4 proteolysis of GLP-1-F7 was shown at selective time points.  Absorbance was monitored at 
280 nm. 
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Figure 4–9.  In Vitro DPP-4 Proteolysis Assay with GLP-1-ES9.   
 
GLP-1-ES9 was fully degraded by 2.5 ng/μL DPP-4 in 30 min.  Absorbance was monitored at 280 
nm. 
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Figure 4–10.  Buffer Stability of GLP-1 Thioamide Derivatives.   
 
Peptides were in DPBS buffer at 37 °C for up to 24 h, then analyzed by HPLC.  A)  GLP-1-FS7; B)  
GLP-1-F7AS8; C)  GLP-1-ES9.  Left:  Intact peptide at time 0;  Right:  Remaining peptide after 24 h.  
Absorbance was monitored at 280 nm. 
 
Auto-Degradation of GLP-1-AS8  GLP-1-AS8 was not stable in 100 mM Tris-HCl 
buffer, pH 8.0 at 37 °C, while GLP-1 was intact after 12 h (Figure 4–11).  In fact, no 
significant difference was observed for the half-lives of GLP-1-AS8 in buffer only, 0.25 
ng/mL DPP-4, or 2.5 ng/mL DPP-4 (Figure 4–11).  In addition, the degradation of GLP-
1-AS8 in buffer was dependent on the pH (Figure 4–12).  In acidic environment, no obvious 
degradation was observed over 4 h.  We hypothesize that GLP-1-AS8 underwent an auto-
degradation process that His7 catalyzed the 6-endo-trig cyclization of the thioamide and 
the terminal amine, by initial deprotection of the amine as well as facilitating subsequent 
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proton transfer steps (Figure 4–13).  The identities of both 2 and 9 could be confirmed by 
HPLC retention time and MALDI MS since they correspond to oxoamide GLP-1 and the 
DPP-4 degradation product GLP-19-36, respectively (Figure 4–14).  Cyclic amidine 6 
could be isolated by HPLC, and upon further incubation, we observed formation of 
byproducts 2 and 9 (Figure 4–15).  We observe much slower (24 h half-life) auto-
degradation of GLP-1-F7A
S
8, further supporting the role of the His7 imidazole group in 
catalyzing the cyclization reaction (Figure 4–11).  We note that this half-life is comparable 
to the half-life of GLP-1-F7A
S
8 in the presence of DPP-4. 
  
  
156 
 
 
 
 
Figure 4–11.  Degradation of GLP-1, GLP-1-AS8 and GLP-1-F7AS8 in Buffer and by DPP-4 
Proteolysis.   
 
A)  35 µM GLP-1 or GLP-1-AS8 was incubated in 100 mM Tris-HCl buffer, pH 8.0 at 37 °C.  B)  35 
µM GLP-1-F7AS8 was incubated in 100 mM Tris-HCl buffer, pH 8.0 at 37 °C.  C)  35 µM GLP-1 or 
GLP-1-AS8 was incubated with 2.5 ng/μL DPP-4 in 100 mM Tris-HCl buffer, pH 8.0 at 37 °C.  D)  35 
µM GLP-1 or GLP-1-AS8 was incubated with 25 ng/μL DPP-4 in 100 mM Tris-HCl buffer, pH 8.0 at 
37 °C 
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Figure 4–12.  pH Dependence of GLP-1-AS8 Degradation in Buffer.   
 
35 µM GLP-1-AS8 was incubated in 10 mM potassium phosphate buffer of various pH at 37 °C for 
4 h.  Absorbance was monitored at 280 nm. 
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Figure 4–13.  Proposed Mechanism of GLP-1-AS8 Auto-Degradation in Buffer.   
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Figure 4–14.  Analysis of GLP-1-AS8 Degradation in Buffer.   
 
GLP-1-AS8 was incubated in 100 mM Tris-HCl buffer, pH 8.0 at 37 °C for 0 h, 4 h, 8 h or 12 h. 
A)  HPLC analysis of the reactions.  Absorbance was monitored at 280 nm.  B)  MALDI-TOF MS 
analysis of the reactions.  C)  UV-Vis absorption of the reactions.  Peaks are labelled corresponding 
to species in Figure 4–13. 
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Figure 4–15.  Degradation of Cyclo GLP-1 in Buffer.   
 
Isolated cyclo GLP-1 (6) was incubated in 100 mM Tris-HCl buffer, pH 8.0 at 37 °C for 0 h, 4 h, 8 
h or 24 h.  Absorbance was monitored at 280 nm. 
 
Competitor Assay  70 µM peptide of interest was mixed with 2.5 ng/µL DPP-4 in 
100 mM Tris buffer (pH 8.0), and full interaction was allowed by 15 min incubation at 
25 °C.  100 µM Ala-Pro-pNA was added to the mixture, and the absorbance change at 410 
nm was monitored for 30 min at 25 °C by the plate reader.  The reaction of 100 µM Ala-
Pro-pNA cleaved by 2.5 ng/µL DPP-4 was also monitored using the same condition. 
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Figure 4–16.  No Inhibition of DPP-4 Activity from Thiopeptides.   
 
When 70 µM of A) GLP-1-FS7, or B) GLP-1-AS8, or C) GIP-YS1 was incubated with 2.5 ng/mL of 
DPP-4, activity of DPP-4 to cleave substrate Ala-Pro-pNA was not affected.  Red trace: Ala-Pro-
pNA cleaved by DPP-4 in the presence of thiopeptides; Orange race: Ala-Pro-pNA alone in the 
presence of thiopeptides; Green trace: Ala-Pro-pNA cleaved by DPP-4 in the absence of 
thiopeptides; Blue trace: Ala-Pro-pNA alone. 
 
Cellular Receptor Activation Assay  The agonist activity of all peptides were 
measured using GPCR assay kits purchased from DiscoveRx (Fremont, CA, USA) 
following the manufacturer’s protocols.  Specifically, cAMP HunterTM eXpress GLP1R 
CHO-K1 GPCR Assay Kit was used for GLP-1 related peptides; and cAMP HunterTM 
eXpress mGIPR CHO-K1 GPCR Assay Kit was used for GIP related peptides.  Peptide of 
interest was incubated with cells for 30 min at 37 °C before cell lysis.  Luminescence 
signals were collected on the plate reader, and fitted to sigmoidal curves to determine the 
EC50 values. 
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Figure 4–17.  GLP-1-AS8 Stability Against DPP-4 Proteolysis and GLP-1R Activation.   
 
A)  Sequences of GLP-1 and GLP-1- AS8.  B)  In vitro DPP-4 proteolysis of GLP-1-AS8.  C)  GLP-
1R activation dose response curves for GLP-1-AS8. 
 
Table 4–7.  In Vitro Half-life and EC50 of All Peptides.   
 
Peptide Half-life (min) Half-life (h) EC50 (pM) 
GLP-1 1.85 ± 0.28  207 ± 42 
GLP-1-AS8  03.44 ± 0.26 2440 ± 398 
GLP-1-ES9 < 5   
GLP-1-F7 2.57 ± 0.07  171 ± 25 
GLP-1-FS7  12.09 ± 0.38 244 ± 29 
GLP-1-F7AS8  25.73 ± 1.06 2715 ± 172 
GIP 5.45 ± 0.08  161 ± 19 
GIP-YS1  67.68 ± 3.47 430 ± 46 
GIP-AS2  60.20 ± 2.86 6522 ± 351 
 
In Vivo Activity Assay  Adult male Sprague Dawley rats (Charles River) were 
individually housed in a temperature- and humidity-controlled environment on a 12h/12h 
light/dark cycle.  Standard rodent chow (Purina 5001) and water were available ad libitum 
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except as noted.  All procedures were approved by the University of Pennsylvania 
Institutional Animal Care and Use Committee.  Oral glucose tolerance testing (OGTT) was 
used to compare the efficacy of GLP-1-FS7 with that of native GLP-1 on glycemic control.  
Rats (n=16) were deprived of food overnight.  Shortly after lights-off the next day, water 
bottles were removed.  A small sample of blood was collected from the tail tip of each rat 
(~10μl), and baseline blood glucose (BG) levels (t=-20 min) were measured using a 
standard glucometer (Accucheck).  Rats were then given an intraperitoneal (IP) injection 
of either vehicle (1 ml/kg sterile 0.9% NaCl, pH 7.0-7.4), GLP-1 (Bachem; 0.50 mg/kg), 
or GLP-1-FS7 (0.50 mg/kg).  Twenty minutes later (t=0 min), another BG reading was taken, 
and each rat received an oral gavage of glucose (2 g/kg).  Subsequent BG readings were 
taken at 20, 40, 60, and 120 min post-gavage from the tail tip.  After the final BG reading 
was taken, food and water were returned. 
The same rats (n=16) were subsequently used for a dose-response analysis of the 
effects of GLP-1-FS7 on glycemic control in an OGTT.  Methods of this dose-response 
study were similar to the first OGTT, except the IP injections consisted of either vehicle (1 
ml/kg sterile 0.9% NaCl, pH 7.0-7.4) or one of three doses of GLP-1-FS7 (0.25, 0.50, or 
1.00 mg/kg). 
Both experiments were conducted using a counterbalanced within-subjects design, 
with treatments separated by approximately one week.  Data were analyzed via repeated 
measures ANOVA (Statistica), accounting for the within-subjects factors of drug and time, 
with p<0.05 considered statistically significant.  Significant results from an ANOVA were 
probed using Student-Newman-Keuls post hoc analyses. 
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